[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 297
1. Chamberlain MC, Glantz MJ: Cerebrospinal fluid-disseminated meningioma. Cancer; 2005 Apr 1;103(7):1427-30
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebrospinal fluid-disseminated meningioma.
  • RESULTS: Treatment-related toxicity was seen in eight patients, including chemical meningitis in eight patients (Grade 2), neutropenia in five patients (Grade 2 in four patients and Grade 3 in one patient), fatigue in one patient (Grade 2), and gastrointestinal toxicity in one patient (Grade 2).
  • CONCLUSIONS: The treatment of CSF-disseminated meningioma, although feasible and comparatively nontoxic, was associated with modest outcomes despite combined systemic and intraventricular chemotherapy.
  • [MeSH-major] Meningioma / secondary
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Brain Neoplasms / pathology. Brain Neoplasms / secondary. Central Nervous System Neoplasms / secondary. Cerebrospinal Fluid / cytology. Female. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Skin Neoplasms / secondary. Spinal Cord Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15690330.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Santhosh K, Kesavadas C, Radhakrishnan VV, Thomas B, Kapilamoorthy TR, Gupta AK: Rhabdoid and papillary meningioma with leptomeningeal dissemination. J Neuroradiol; 2008 Oct;35(4):236-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdoid and papillary meningioma with leptomeningeal dissemination.
  • Rhabdoid meningioma is a rare variant of meningioma classified as grade III under the new World Health Organization (WHO) classification of brain tumors.
  • We report here a case of rhabdoid meningioma in a young man, operated on twice previously, who presented with multiple CSF areas of seeding in the brain and spinal cord.
  • This particular histological subtype of meningioma has a poor prognosis and must be treated aggressively.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Spinal Cord Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18325590.001).
  • [ISSN] 0150-9861
  • [Journal-full-title] Journal of neuroradiology. Journal de neuroradiologie
  • [ISO-abbreviation] J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


3. Shayanfar N, Mashayekh M, Mohammadpour M: Expression of progestrone receptor and proliferative marker ki 67 in various grades of meningioma. Acta Med Iran; 2010 May-Jun;48(3):142-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of progestrone receptor and proliferative marker ki 67 in various grades of meningioma.
  • The aim of present study is to evaluate the status of progesterone receptor (PR) and proliferation marker Ki67 in various grades of meningioma in a group of Iranian patients.
  • 78 cases of meningioma were selected from the file of a hospital university.
  • PR were positive in 61/63 (96.8%) of grade I tumors, 2/10 (20%) of grade II, and 0/5 (0%) of grade III tumors.
  • Ki67 LI was %2.98 +/- 2.27 in grade I tumors, %9.30 +/- 5.79 in grade II tumors and %34.00 +/- 5.47 in grade III tumors.
  • For both markers, differences between grade I, II and III tumors were significant (P < 0.001).
  • There was a reverse relationship between mean of Ki67 LI and PR status, with increasing grade of tumor.
  • [MeSH-major] Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptors, Progesterone / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Iran. Male. Middle Aged. Neoplasm Staging. Staining and Labeling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21137648.001).
  • [ISSN] 0044-6025
  • [Journal-full-title] Acta medica Iranica
  • [ISO-abbreviation] Acta Med Iran
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Progesterone
  •  go-up   go-down


Advertisement
4. Dijkstra M, van Nieuwenhuizen D, Stalpers LJ, Wumkes M, Waagemans M, Vandertop WP, Heimans JJ, Leenstra S, Dirven CM, Reijneveld JC, Klein M: Late neurocognitive sequelae in patients with WHO grade I meningioma. J Neurol Neurosurg Psychiatry; 2009 Aug;80(8):910-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late neurocognitive sequelae in patients with WHO grade I meningioma.
  • The aim of the present study was therefore to document the extent and nature of neurocognitive deficits in patients with World Health Organization (WHO) grade I meningioma after treatment.
  • METHODS: 89 patients with WHO grade I meningioma who underwent surgery with or without adjuvant radiotherapy were individually matched to 89 healthy controls for age, sex and educational level.
  • RESULTS: Compared with healthy controls, patients with meningioma showed significant impairments in executive functioning (p<0.001), verbal memory (p<0.001), information processing capacity (p = 0.001), psychomotor speed (p = 0.001) and working memory (p = 0.006).
  • CONCLUSIONS: Meningioma patients are characterised by long term deficits in neurocognitive functioning that can partly be attributed to the use of antiepileptic drugs and tumour location but not to the use of radiotherapy.
  • [MeSH-major] Cognition Disorders / etiology. Meningioma / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cross-Sectional Studies. Epilepsy / etiology. Female. Functional Laterality / physiology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neuropsychological Tests. Neurosurgical Procedures. Psychomotor Performance / physiology. Socioeconomic Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18653549.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


5. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, Black PM, Giovannini M, Carroll RS, Kalamarides M: Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res; 2010 Aug 15;16(16):4155-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status.
  • EXPERIMENTAL DESIGN: We identified genetic alterations associated with histologic progression of 36 paired meningioma samples in 18 patients using 500K SNP genotyping arrays and NF2 gene sequencing.
  • RESULTS: The most frequent chromosome alterations observed in progressing meningioma samples are early alterations (i.e., present both in lower- and higher-grade samples of a single patient).
  • In our series, NF2 gene inactivation was an early and frequent event in progressing meningioma samples (73%).
  • Chromosome alterations acquired during progression from grade I to grade II meningioma were not recurrent.
  • Progression to grade III was characterized by recurrent genomic alterations, the most frequent being CDKN2A/CDKN2B locus loss on 9p.
  • This pattern of alterations could thus be used as markers in clinical practice to identify tumors prone to progress among grade I meningiomas.
  • [MeSH-major] Genes, Neurofibromatosis 2. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Gene Dosage. Gene Expression. Gene Expression Profiling. Genotype. Humans. Loss of Heterozygosity. Male. Middle Aged. Mutation. Oligonucleotide Array Sequence Analysis. Polymorphism, Single Nucleotide. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682713.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Nagasaka T, Gunji M, Hosokai N, Hayashi K, Fujino M, Ikeda H, Ito M, Inao S: Fluorescent in situ hybridization 1p/19q deletion/imbalance analysis of low-grade and atypical meningiomas. Neurol Med Chir (Tokyo); 2010 Jan;50(1):27-32; discussion 32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescent in situ hybridization 1p/19q deletion/imbalance analysis of low-grade and atypical meningiomas.
  • The chromosomal 1p/19q state was analyzed in 16 low-grade meningiomas and 7 atypical meningiomas using fluorescent in situ hybridization (FISH) analysis.
  • Chromosome 1p aberrations were observed in all atypical meningiomas, but in only one low-grade meningioma.
  • A small group of low-grade meningioma showed 19q aberrations.
  • Patients with low-grade meningioma with chromosomal instability of 1p/19q should be followed up carefully.
  • [MeSH-major] Genetic Predisposition to Disease / genetics. In Situ Hybridization, Fluorescence / methods. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / genetics. Meningioma / diagnosis. Meningioma / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Allelic Imbalance / genetics. Chromosomal Instability / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Mutational Analysis. Female. Gene Deletion. Genetic Markers / genetics. Genetic Testing. Genotype. Humans. Male. Middle Aged. Mutation / genetics. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098021.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


7. Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Malmer B, Lönn S, Söderberg K, Feychting M: Prior hospitalization for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):643-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prior hospitalization for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk.
  • We conducted a case-control study to evaluate the preclinical association between epilepsy, diabetes, and stroke and primary adult brain tumors.
  • We first identified all 1,501 low-grade glioma, 4,587 high-grade glioma (HGG), and 4,193 meningioma cases reported to the Swedish Cancer Registry from 1987 to 1999.
  • Results are similar for glioblastoma multiforme, low-grade glioma, and meningioma.
  • [MeSH-major] Brain Neoplasms / etiology. Diabetes Complications. Diabetes Mellitus / therapy. Epilepsy / complications. Glioma / etiology. Meningeal Neoplasms / etiology. Meningioma / etiology. Stroke / complications
  • [MeSH-minor] Adult. Age of Onset. Aged. Case-Control Studies. Female. Hospitalization. Humans. Male. Middle Aged. Risk Factors. Time Factors


8. Moradi A, Semnani V, Djam H, Tajodini A, Zali AR, Ghaemi K, Nikzad N, Madani-Civi M: Pathodiagnostic parameters for meningioma grading. J Clin Neurosci; 2008 Dec;15(12):1370-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathodiagnostic parameters for meningioma grading.
  • In this study the relationship between pathodiagnostic parameters, histological grade, and MIB-1 monoclonal antibody expression in meningioma diagnosed over 10 years in Shohada Hospital, Tehran, was assessed.
  • All slides stained with hematoxylin and eosin were reviewed by two independent pathologists and all the diagnoses reconfirmed; histological anaplasia was classified according to the grading of the WHO Working Group 2000 as benign (Grade I), atypical with incipient signs of anaplasia (Grade II), or overtly anaplastic (Grade III).
  • Histopathological study of completely resected meningiomas showed that loss of architecture, frequent mitotic figures, a high cellularity, increased nucleo-cytoplasmic ratio, a prominent nucleolus, brain invasion, and necrosis were correlated with the grade of the meningiomas.
  • Overall, the mitotic count was the most important marker for tumor grade.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Iran. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Ubiquitin-Protein Ligases / metabolism. X-Ray Microtomography. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819804.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


9. Wu YT, Lin JW, Wang HC, Lee TC, Ho JT, Lin YJ: Clinicopathologic analysis of rhabdoid meningioma. J Clin Neurosci; 2010 Oct;17(10):1271-5
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of rhabdoid meningioma.
  • Rhabdoid meningioma is an uncommon variant of meningioma, and was classified separately for the first time in the 2000 World Health Organization's classification of tumors of the nervous system.
  • Because it often shows malignant histological features and follows an aggressive clinical course, it has been classified as a grade III neoplasm.
  • From 13 patients (seven male, six female), 19 specimens of rhabdoid meningioma were obtained between 2001 and 2009.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Intranuclear Inclusion Bodies / pathology. Ki-67 Antigen / metabolism. Male. Middle Aged. S100 Proteins / metabolism. Vimentin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20537897.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / S100 Proteins; 0 / Vimentin
  •  go-up   go-down


10. Binello E, Bederson JB, Kleinman GM: Hemangiopericytoma: collision with meningioma and recurrence. Neurol Sci; 2010 Oct;31(5):625-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemangiopericytoma: collision with meningioma and recurrence.
  • This report provides the first documentation in the literature of a hemangiopericytoma colliding with a meningioma, and recurring after treatment with gross total resection.
  • Results were classically representative of a hemangiopericytoma (World Health Organization grade II) and of a meningioma (World Health Organization grade I).
  • [MeSH-major] Brain Neoplasms / complications. Hemangiopericytoma / complications. Meningeal Neoplasms / complications. Meningioma / complications. Neoplasm Recurrence, Local / complications
  • [MeSH-minor] Adult. Antigens, CD34 / metabolism. Humans. Magnetic Resonance Imaging. Male. Recurrence

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198500.001).
  • [ISSN] 1590-3478
  • [Journal-full-title] Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  • [ISO-abbreviation] Neurol. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


11. Somerset HL, Kleinschmidt-DeMasters BK, Rubinstein D, Breeze RE: Osteochondroma of the convexity: pathologic-neuroimaging correlates of a lesion that mimics high-grade meningioma. J Neurooncol; 2010 Jul;98(3):421-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteochondroma of the convexity: pathologic-neuroimaging correlates of a lesion that mimics high-grade meningioma.
  • The bright signals were interpreted as showing multifocal hemorrhage and the mass was felt to be a convexity meningioma.
  • Rare convexity osteochondromas may be mistaken for high-grade meningiomas on neuroimaging studies; their avascular nature, coupled with their complex signal pattern can serve as clues to the correct pre-operative diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Dura Mater / pathology. Meningeal Neoplasms / physiopathology. Meningioma / physiopathology. Osteochondroma / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging / methods. Statistics as Topic

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Osteochondroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012156.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Lee JW, Kang KW, Park SH, Lee SM, Paeng JC, Chung JK, Lee MC, Lee DS: 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging; 2009 Oct;36(10):1574-82
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma.
  • PURPOSE: The purpose of this study was to investigate the role of (18)F-fluorodeoxyglucose (FDG) PET in detecting high-grade meningioma and predicting the recurrence in patients with meningioma after surgical resection.
  • METHODS: Fifty-nine patients (27 men and 32 women) with intracranial meningioma who underwent preoperative FDG PET and subsequent surgical resection were enrolled.
  • The tumor to gray matter ratio (TGR) of FDG uptake was calculated and a receiver-operating characteristic (ROC) curve of the TGR was drawn to determine the cutoff value of the TGR for detection of high-grade meningioma.
  • Further, univariate analysis with the log-rank test was performed to assess the predictive factors of meningioma recurrence.
  • RESULTS: The TGR in high-grade meningioma (WHO grade II and III) was significantly higher than that in low-grade ones (WHO grade I) (p=0.002) and significantly correlated with the MIB-1 labeling index (r=0.338, p=0.009) and mitotic count of the tumor (r=0.284, p=0.03).
  • The ROC analysis revealed that the TGR of 1.0 was the best cutoff value for detecting high-grade meningioma with a sensitivity of 43%, specificity of 95%, and accuracy of 81%.
  • In the log-rank test, the TGR, MIB-1 labeling index, presence of brain invasion, and WHO grade were significantly associated with tumor recurrence.
  • The cumulative recurrence-free survival rate of patients with a TGR of 1.0 or less was significantly higher than that of patients with a TGR of more than 1.0 (p=0.0003) CONCLUSION: FDG uptake in meningioma was the significant predictive factor of tumor recurrence and significantly correlated with the proliferative potential of the tumor.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Meningioma / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Fluorine Radioisotopes. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography. ROC Curve

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377904.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Tu PH, Giannini C, Judkins AR, Schwalb JM, Burack R, O'Neill BP, Yachnis AT, Burger PC, Scheithauer BW, Perry A: Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol; 2005 Aug 20;23(24):5718-27
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma.
  • PURPOSE: Although rare overall, marginal zone B-cell lymphoma (MZBCL) is the most common primary low-grade CNS lymphoma reported in the literature.
  • RESULTS: CNS MZBCLs preferentially affect middle-aged women (female-to-male ratio, 4:1), with 93% presenting as dural-based masses mimicking meningioma.
  • CONCLUSION: Our data suggest that intracranial MZBCL is an indolent primary CNS lymphoma that typically presents as a meningioma-like dural-based mass.
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 3. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Meningioma / pathology. Middle Aged. Translocation, Genetic. Trisomy

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16009945.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Bollag RJ, Vender JR, Sharma S: Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence. Neuropathology; 2010 Jun;30(3):279-87
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic meningioma: progression from atypical and chordoid morphotype with morphologic spectral variation at recurrence.
  • The current WHO 2007 classification divides meningiomas into a 3-grade prognostic hierarchy.
  • Recent literature evokes two pathways to disease progression in meningiomas akin to a comparable paradigm in gliomas, but without similar prognostic connotation: de novo anaplastic meningioma (better prognosis), and transformed meningioma (worse prognosis).
  • We present two adult cases of transformed meningiomas that display a spectrum of morphologic progression.
  • Case 1 at presentation showed a random admixture of meningothelial, atypical and anaplastic meningioma.
  • The tumor recurred as anaplastic meningioma.
  • Case 2 presented as a chordoid meningioma, but recurred as anaplastic meningioma mainly at the invasive front in transition with residual chordoid pattern.
  • In accordance with the dire prognosis for anaplastic meningioma, both patients succumbed to their disease within 2 months of recurrence.
  • The present study highlights two main points: First, that proper recognition of focal high-grade areas in a heterogeneous low-grade meningioma (case 1) provides critical morphologic clues to spatial histologic progression and predicts aggressive biologic behavior, as evidenced by progression to frankly anaplastic meningioma at recurrence.
  • Second, the presence of papillary in addition to anaplastic areas, in the recurrence of a previously diagnosed chordoid meningioma supports the ostensibly heightened transforming potential of grade II meningiomas, but also reflects on the morphologic heterogeneity of high-grade meningiomas, and their potentially diverse pathways of progression.
  • Future molecular genetic correlates, akin to those characterized in gliomas, could help stratify prognostic subcategories to refine meningioma grading, and govern optimal therapeutic strategies.
  • [MeSH-major] Choroid Plexus Neoplasms / diagnosis. Choroid Plexus Neoplasms / pathology. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningioma / diagnosis. Meningioma / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780983.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


15. Liu Y, Tian RF, Li YM, Liu WP, Cao L, Yang XL, Cao WD, Zhang X: The expression of seven 14-3-3 isoforms in human meningioma. Brain Res; 2010 Jun 8;1336:98-102
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of seven 14-3-3 isoforms in human meningioma.
  • However, the expression of seven 14-3-3 isoforms in meningioma still remains unknown.
  • This study is the first examination of 14-3-3 isoforms in three grades of meningioma by immunohistochemistry.
  • 14-3-3epsilon, zeta and theta were specifically expressed in meningioma, and their expression levels increased with the increase of pathological grade of meningioma.
  • The 14-3-3 eta, beta, gamma and sigma isoforms were negatively expressed in meningioma.
  • In conclusion, The 14-3-3 epsilon, zeta and theta may be involved in tumorigenesis of meningioma and be efficient markers for predicting the degree of malignancy in meningioma.
  • [MeSH-major] 14-3-3 Proteins / biosynthesis. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Protein Isoforms / biosynthesis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20388496.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / Protein Isoforms
  •  go-up   go-down


16. Katz TS, Amdur RJ, Yachnis AT, Mendenhall WM, Morris CG: Pushing the limits of radiotherapy for atypical and malignant meningioma. Am J Clin Oncol; 2005 Feb;28(1):70-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pushing the limits of radiotherapy for atypical and malignant meningioma.
  • PURPOSE: The purpose of this study was to report the outcome of an extremely aggressive radiotherapy program in patients with atypical and malignant meningioma (60 Gy at 1.5 Gy per fraction twice daily +/- radiosurgery boost).
  • METHODS AND MATERIALS: Thirty-six patients received radiotherapy with curative intent between 1984 and 1999 for atypical (27 patients) or malignant (9 patients) meningioma.
  • The complication rate for those treated with accelerated hyperfractionated radiotherapy was dramatically higher (grade 3-5: 55% vs. 0%, grade 4-5: 27% vs. 0%.
  • CONCLUSION: Our data suggests that 50 to 60 Gy delivered with conventional, once-daily fractionation is probably the optimal schedule for atypical and malignant meningioma.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose Fractionation. Female. Humans. Male. Middle Aged. Radiosurgery. Survival Rate

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15685038.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Tao Y, Wei Q, Xu Z, Bai R, Li Y, Luo C, Dong Y, Gao G, Lu Y: Holistic and network analysis of meningioma pathogenesis and malignancy. Biofactors; 2006;28(3-4):203-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Holistic and network analysis of meningioma pathogenesis and malignancy.
  • Meningiomas, which originate from arachnoid cells and constitute the largest subgroup of all intracranial tumors, are generally benign, yet have the capacity to progress into a higher histological grade of malignancy associated with an increase in biological aggressivity and/or capacity to recur.
  • To elucidate meningioma pathogenesis and malignancy, we applied a holistic and network approach analyzing cDNA and tissue microarray results.
  • A potential pathway leading to meningioma angiogenesis, apoptosis and proliferation was evidenced as well as a regulatory network of the biomarkers including Ki-67, AR, CD34, P53, c-MYC, etc. which might support clinical research.
  • Some genes are first reported that could explain why radiation induces meningioma and why more female than male patients are affected.
  • Further, we present the hypothesis that HIV-Tat protein might have a close relationship with meningioma pathogenesis and malignancy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Meningioma / chemistry. Meningioma / pathology. Proteome / chemistry
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD29 / genetics. Child. Child, Preschool. China / epidemiology. Down-Regulation. Female. Gene Expression Regulation, Neoplastic. Gene Products, tat / metabolism. Humans. Immunoblotting. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Sex Factors. Thioredoxins / analysis. Up-Regulation

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473381.001).
  • [ISSN] 0951-6433
  • [Journal-full-title] BioFactors (Oxford, England)
  • [ISO-abbreviation] Biofactors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Biomarkers, Tumor; 0 / Gene Products, tat; 0 / Proteome; 52500-60-4 / Thioredoxins
  •  go-up   go-down


18. Chamberlain MC, Tsao-Wei DD, Groshen S: Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol; 2006 Jul;78(3):271-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy with CPT-11 for recurrent meningioma.
  • BACKGROUND: A prospective Phase II study of irinotecan (CPT-11) in adult patients with recurrent surgery and radiotherapy-refractory WHO Grade I meningioma.
  • METHODS: Sixteen patients (5 men; 11 women) ages 48-70 years (median 62.5), with recurrent meningioma were treated.
  • CPT-11 related-toxicity (> or = grade 3) included diarrhea (6 occurrences, 19% all cycles administered), granulocytopenia (6, 19%), leukopenia (5, 16%), thrombocytopenia (3, 10%) and anemia (3, 10%).
  • Using CPT-11 in this moderately toxic dose schedule failed to demonstrate efficacy in this cohort of adult patients with recurrent surgery and radiotherapy-refractory meningioma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Meningioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628476.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


19. Pfisterer WK, Coons SW, Aboul-Enein F, Hendricks WP, Scheck AC, Preul MC: Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue. J Neurooncol; 2008 Mar;87(1):43-50
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implicating chromosomal aberrations with meningioma growth and recurrence: results from FISH and MIB-I analysis of grades I and II meningioma tissue.
  • The fluorescence in situ hybridization (FISH) technique was used in 111 WHO grades I and II meningioma patients.
  • Significant differences for MIB-1 labeling were found between grades I and II tumors (p < 0.001), and between grade I tumors that recurred and those that did not recur (p < 0.001).
  • Chromosomal aberrations were detected with FISH analysis in nearly 50% of grade I, and in 93% of grade II meningiomas.
  • The findings suggest that adding FISH analysis may allow better prediction of possible meningioma recurrence and may be a useful adjunct for therapy decisions.
  • [MeSH-major] Chromosome Aberrations. In Situ Hybridization, Fluorescence. Ki-67 Antigen / metabolism. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Humans. Immunohistochemistry. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18060363.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


20. Sheehan JP, Williams BJ, Yen CP: Stereotactic radiosurgery for WHO grade I meningiomas. J Neurooncol; 2010 Sep;99(3):407-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for WHO grade I meningiomas.
  • Meningiomas represent a common intracranial tumor in the adult population.
  • As success was observed in this setting, radiosurgery has gradually expanded its role so as to treat convexity meningiomas; it is also used as an upfront treatment for patients for whom clinical and neuro-imaging findings are consistent with a meningioma.
  • Most large series demonstrate tumor control rates for patients with grade I meningiomas in excess of 85%.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20734218.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


21. Lakhdar F, Arkha Y, El Ouahabi A, Melhaoui A, Rifi L, Derraz S, El Khamlichi A: Intracranial meningioma in children: different from adult forms? A series of 21 cases. Neurochirurgie; 2010 Aug;56(4):309-14
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial meningioma in children: different from adult forms? A series of 21 cases.
  • The goal of this study of pediatric meningiomas was to establish their epidemiological profile as well as their clinical and radiological features, to assess the long-term outcome, and compare this result with adult meningioma.
  • PATIENT AND METHODS: We conducted a retrospective study from June 1983 to June 2007; during this period 521 patients underwent surgery for primary meningioma at the Rabat Hospital, Department of Neurosurgery.
  • Surgery achieved a Simpson grade I resection in 47%; 62% of the tumors were grade I and 24% were grade II based on World Health Organization pathological classification.
  • CONCLUSION: Pediatric meningiomas are larger than those found in the adult population; there is a male predominance with high incidence of a cystic component and high-grade meningiomas, thus explaining the increased recurrence rate despite the multimodal treatment.
  • [MeSH-major] Aging / pathology. Meningioma / pathology. Supratentorial Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20615516.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


22. Halliday J, Fernandes H: Meningioma recurrence: the efficacy and cost-effectiveness of current screening. Br J Neurosurg; 2010 Feb;24(1):55-61
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningioma recurrence: the efficacy and cost-effectiveness of current screening.
  • Scanning of post-operative meningioma patients to detect tumour recurrence is common practice.
  • The objective of this study was to determine current post-operative scanning use, in particular its timing and frequency in relation to meningioma recurrence rate.
  • We performed a retrospective analysis of the surgical records of patients that underwent meningioma excision between 1998 and 2003 in Addenbrookes Hospital, and their follow-up scans up to 9 years post-surgery.
  • Age at surgery, Simpson grade of surgical removal, tumour location, WHO histological grade, post-surgical radiotherapy, dates of meningioma recurrences, and dates of post-operative CT and MRI scans up to present, were recorded for each patient.
  • Using logistic regression we found that WHO grade and post-surgical radiotherapy were the strongest predictors of meningioma recurrence.
  • We found that timing and frequency of scans between patients of the same stage and grade is highly variable.
  • Data suggests that the role for regular short term post-operative scanning of WHO grade 1 meningioma patients, a group that form the bulk of meningioma patients, is limited, and should only be performed in select, clinically indicated cases.
  • Data from a greater number of patients with WHO grade 2 and 3 meningiomas needs to analysed before definite conclusions can be made about the regularity of post-operative scanning in these patients.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cost-Benefit Analysis. Female. Humans. Magnetic Resonance Imaging / economics. Male. Medical Audit. Middle Aged. Regression Analysis. Retrospective Studies. Time Factors. Tomography, X-Ray Computed / economics. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20158354.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Askoxylakis V, Zabel-du Bois A, Schlegel W, Debus J, Huber P, Milker-Zabel S: Patterns of failure after stereotactic radiotherapy of intracranial meningioma. J Neurooncol; 2010 Jul;98(3):367-72
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after stereotactic radiotherapy of intracranial meningioma.
  • The aim of this work is to evaluate patterns of failure in patients with recurrent meningioma after stereotactic radiotherapy.
  • Of 411 patients with intracranial meningioma treated with radiotherapy at our institution, 22 patients with local tumor progression diagnosed by magnetic resonance imaging (MRI) after radiotherapy (RT) were identified and further investigated.
  • The histologic grade of the meningiomas was World Health Organization (WHO) grade I in 54.5%, WHO grade II in 27.3%, and WHO grade III in 9.1% of cases.
  • Median recurrence-free survival was 46 months for patients with benign meningioma (WHO grade I) and 31.5 months for patients with higher-grade meningioma (WHO grade II/III).
  • In the WHO grade I group, three recurrences were central and nine were marginal, whereas in the WHO grade II/III group seven recurrences were central and one was marginal.
  • Median time to local tumor progression and site of local recurrence significantly depended on histological grade of meningioma.
  • Regarding site of failure, improvement of dose coverage for benign meningiomas and dose escalation for high-grade tumors might further improve therapy outcome.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Karnofsky Performance Status. Male. Middle Aged. Retrospective Studies. Treatment Failure. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012910.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Al-Habib A, Lach B, Al Khani A: Intracerebral rhabdoid and papillary meningioma with leptomeningeal spread and rapid clinical progression. Clin Neuropathol; 2005 Jan-Feb;24(1):1-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracerebral rhabdoid and papillary meningioma with leptomeningeal spread and rapid clinical progression.
  • OBJECTIVE AND IMPORTANCE: Rhabdoid meningioma (RM) is a relatively new, Grade III tumor entity according to the latest WHO classification.
  • We report rhabdoid and partly papillary, highly anaplastic, intracerebral meningioma with diffuse leptomeningeal spread and distant SCF metastasis to the cervical cord.
  • RESULTS: Histological examination revealed rhabdoid and papillary meningioma with high proliferation rate (80% of MIB1-positive cells), necrosis and extensive brain invasion.
  • CONCLUSION: This is a rare example of mixed, rhabdoid and papillary variant of meningioma, located entirely within the brain parenchyma and accompanied by a fulminant clinical course.
  • [MeSH-major] Arachnoid / pathology. Frontal Lobe. Meningeal Neoplasms / secondary. Meningeal Neoplasms / surgery. Meningioma / secondary. Meningioma / surgery. Pia Mater / pathology
  • [MeSH-minor] Adult. Brain / pathology. Disease Progression. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696777.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 34
  •  go-up   go-down


25. Tena-Suck ML, Collado-Ortìz MA, Salinas-Lara C, García-López R, Gelista N, Rembao-Bojorquez D: Chordoid meningioma: a report of ten cases. J Neurooncol; 2010 Aug;99(1):41-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chordoid meningioma: a report of ten cases.
  • Chordoid meningioma is a rare variant of meningioma with histological features resembling those of chordoma.
  • This tumor has a great risk of recurrence and aggressive growth (WHO grade II).
  • This study was done to document the clinical and pathological features of ten patients with chordoid meningioma who submitted to surgery at the National Institute of Neurology and Neurosurgery in Mexico City.
  • Chordoid meningioma, World Health Organization grade II, is an uncommon variant of meningioma with a propensity for aggressive behavior and increased likelihood of recurrence.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / metabolism. Cell Adhesion Molecules / metabolism. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Mucin-1 / metabolism. Retrospective Studies. S100 Proteins / metabolism. Vimentin / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - TEN.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20094774.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / S100 Proteins; 0 / Vimentin
  •  go-up   go-down


26. Shimada S, Ishizawa K, Hirose T: Expression of E-cadherin and catenins in meningioma: ubiquitous expression and its irrelevance to malignancy. Pathol Int; 2005 Jan;55(1):1-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of E-cadherin and catenins in meningioma: ubiquitous expression and its irrelevance to malignancy.
  • According to the provided World Health Organization (WHO) grading, 84, 18 and five cases were classified as grade I, II and III, respectively.
  • Even in meningiomas of more than grade II, the expressions of cell adhesion molecules were detected in all cases.
  • The present study demonstrates that cell adhesion molecules are ubiquitously expressed in all variants of meningioma and may be involved in the tumor morphogenesis.
  • The present study also suggests that these markers may be useful for the differential diagnosis of meningioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cadherins / biosynthesis. Cytoskeletal Proteins / biosynthesis. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Hemangioblastoma / metabolism. Hemangioblastoma / pathology. Hemangiopericytoma / metabolism. Hemangiopericytoma / pathology. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660696.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Cytoskeletal Proteins
  •  go-up   go-down


27. Li Y, Shi JT, An YZ, Zhang TM, Fu JD, Zhang JL, Zhao JZ: Sphenoid wing meningioma en plaque: report of 37 cases. Chin Med J (Engl); 2009 Oct 20;122(20):2423-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphenoid wing meningioma en plaque: report of 37 cases.
  • BACKGROUND: Sphenoid wing meningioma en plaque is a special morphological subgroup of intracranial meningiomas, defined by a carpet-like, soft tissue component that infiltrates the dura and invades the sphenoid wing and orbit associated with a significant hyperostosis.
  • This report summarized our experiences in 37 patients with sphenoid wing meningioma en plaque who had been treated with transcranio-orbital approach surgery.
  • RESULTS: Simpson grade II resection was achieved in 9 patients, Simpson grade III in 22 patients and Simpson grade IV in 6 patients.
  • CONCLUSIONS: Sphenoid wing meningioma en plaque, mainly meningothelial meningiomas, are more likely to produce adjacent hyperostosis and have characteristic radiological appearances.
  • [MeSH-major] Meningioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079153.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


28. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A: Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology; 2007 Apr;27(2):114-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma.
  • Although most are benign, between 5% and 15% of meningiomas are atypical (grade II) whereas 1-2% are anaplastic meningiomas (grade III).
  • Although histological grade is the most relevant prognostic factor, there are some unusual cases in which establishing a diagnosis of high-grade meningioma following 2000 World Health Organization (WHO) histological criteria is extremely difficult.
  • Therefore, the aim of the present study was to evaluate the predictive value of Ki-67 labeling index and its contribution to current WHO classification in predicting tumor recurrence and overall survival in patients with high-grade meningiomas.
  • Median Ki-67 labeling index in the whole series was 7.0 (0.5-31.5) with no differences with respect to the histological grade (P = 0.87).
  • More importantly, this predictive value was maintained in both patients with atypical and patients with anaplastic meningioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / metabolism. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Prognosis. ROC Curve. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neuropathology. 2008 Feb;28(1):106-7 [18181839.001]
  • (PMID = 17494511.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


29. Couldwell WT, Cole CD, Al-Mefty O: Patterns of skull base meningioma progression after failed radiosurgery. J Neurosurg; 2007 Jan;106(1):30-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of skull base meningioma progression after failed radiosurgery.
  • METHODS: The authors report 13 cases of benign skull base meningiomas (World Health Organization Grade I) that demonstrated progression after radiosurgical treatment as a primary or an adjuvant therapy.
  • CONCLUSIONS: Skull base meningioma growth can be aggressive after failed radiosurgery in some patients, and treatment failure can occur at long intervals following treatment.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Radiosurgery. Skull Base Neoplasms / pathology. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm, Residual. Retrospective Studies. Treatment Failure

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236485.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Bacciu A, Piazza P, Di Lella F, Sanna M: Intracanalicular meningioma: clinical features, radiologic findings, and surgical management. Otol Neurotol; 2007 Apr;28(3):391-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracanalicular meningioma: clinical features, radiologic findings, and surgical management.
  • PATIENTS: Thirteen consecutive patients with pathologically confirmed intracanalicular meningioma surgically treated between December 1988 and July 2006.
  • The postoperative facial nerve function was either excellent or good (House-Brackmann Grade I or II) in 10 cases (77%) and acceptable (Grade III) in one case.
  • On account of a lack of specific symptoms and the limited diagnostic findings, preoperative diagnosis of intracanalicular meningioma still represents a diagnostic challenge.
  • [MeSH-major] Ear Neoplasms / pathology. Ear Neoplasms / surgery. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Otologic Surgical Procedures / methods. Vestibular Aqueduct / pathology. Vestibular Aqueduct / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Audiometry, Pure-Tone. Evoked Potentials, Auditory, Brain Stem. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Complications / diagnosis. Postoperative Complications / epidemiology. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287658.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Ghosal N, Furtado SV, Santosh V, Sridhar M, Hegde AS: Co-existing fibrous dysplasia and atypical lymphoplasmacyte-rich meningioma. Neuropathology; 2007 Jun;27(3):269-72
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-existing fibrous dysplasia and atypical lymphoplasmacyte-rich meningioma.
  • We report an unusual and extremely rare case of coexisting fibrous dysplasia of the sphenoid sinus with atypical lymphoplasmacyte rich meningioma (World Health Organization Grade II), right frontal lobe in a 25-year-old male.
  • [MeSH-major] Fibrous Dysplasia, Monostotic / complications. Fibrous Dysplasia, Monostotic / pathology. Meningeal Neoplasms / complications. Meningeal Neoplasms / pathology. Meningioma / complications. Meningioma / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male. Sphenoid Bone / pathology. Sphenoid Sinus / pathology

  • Genetic Alliance. consumer health - Fibrous Dysplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645241.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


32. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors.
  • The second aim was to confirm if cathepsin B and/or cathepsin L and their endogenous inhibitors were also prognostic parameters in the clinical study of 119 patients with meningioma.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • In vitro invasion assays of the malignant meningioma cells were used to assess the invasive potential related to the cysteine cathepsins.
  • As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.
  • Univariate and multivariate analyses were used to compare these parameters with established biological markers of meningioma recurrence in 119 patients with meningiomas.
  • Matrigel invasion of malignant meningioma cells was significantly altered by modulating cathepsin B activity and by stefin B silencing.
  • In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.
  • As expected, WHO grade, age, and Simpson grade (complete tumor resection) were prognostic, with Simpson grade only relevant in the short term (up to 90 months) but not in longer-term follow-up.
  • CONCLUSIONS: The data indicate that the cysteine cathepsins and their inhibitors are involved in a process related to early meningioma recurrence, regardless of their histological classification.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cathepsin B / genetics. Cystatin A / genetics. Cystatin B / genetics. Female. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neurosurgical Procedures. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747051.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CSTB protein, human; 0 / Cystatin A; 0 / Cysteine Proteinase Inhibitors; 88844-95-5 / Cystatin B; EC 3.4.22.1 / CTSB protein, human; EC 3.4.22.1 / Cathepsin B
  •  go-up   go-down


33. Sanai N, Sughrue ME, Shangari G, Chung K, Berger MS, McDermott MW: Risk profile associated with convexity meningioma resection in the modern neurosurgical era. J Neurosurg; 2010 May;112(5):913-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk profile associated with convexity meningioma resection in the modern neurosurgical era.
  • RESULTS: Between 1997 and 2007, 141 consecutive patients (median age 48 years, range 18-95 years) underwent resection of a supratentorial convexity meningioma.
  • A Simpson Grade 0 or 1 resection was achieved in 122 patients (87%).
  • One hundred six tumors (75%) were WHO Grade I, whereas 35 (25%) were WHO Grade II.
  • [MeSH-major] Meningioma / pathology. Meningioma / surgery. Neurosurgical Procedures / methods. Radiosurgery / methods. Supratentorial Neoplasms / pathology. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Complications / epidemiology. Intraoperative Complications / prevention & control. Male. Microsurgery / instrumentation. Middle Aged. Risk Assessment. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19645533.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Kozler P, Benes V, Netuka D, Kramár F, Hrabal P, Charvát F: Chordoid meningioma: presentation of two case reports, review of the literature, and plea for data standardisation. J Neurooncol; 2008 May;88(1):115-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chordoid meningioma: presentation of two case reports, review of the literature, and plea for data standardisation.
  • Chordoid meningioma is a rare variant of meningioma with histological features resembling those of chordoma.
  • This tumour should have a greater risk of recurrence and aggressive growth (WHO grade II).
  • We report two cases of chordoid meningioma occurring in adult female patients.
  • In our two patients (aged 28 and 60 years with chordoid meningioma of the convexity and left-sided outer sphenoid wing, respectively) we centred on some rarely discussed aspects of the tumour.
  • In both cases, the tumour was removed by radical surgery (Simpson grade I resection) with a normal post-operative course.
  • We regard the factors under consideration in our study (i.e. absence of edema, dural supply, low VEGF expression and radical Simpson grade I resection) as an important contribution to the discussion of the biological behaviour of chordoid meningioma.
  • [MeSH-major] Meningioma / pathology
  • [MeSH-minor] Adult. Biopsy. Cerebrovascular Circulation. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Middle Aged. Neurosurgical Procedures. Vimentin / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18320142.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin
  •  go-up   go-down


35. Moiyadi AV, Sridhar E, Gupta T, Ramadwar M: A primary optic nerve sheath chordoid meningioma. J Clin Neurosci; 2010 Mar;17(3):397-9
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A primary optic nerve sheath chordoid meningioma.
  • Most of these are World Health Organization Grade I meningiomas.
  • The chordoid variant of meningioma is an infrequent tumor and extremely uncommon among primary ONMs.
  • Histology revealed a chordoid meningioma.
  • [MeSH-major] Choroid Neoplasms. Meningeal Neoplasms. Meningioma. Optic Nerve Neoplasms
  • [MeSH-minor] Adult. Female. Gadolinium. Humans. Magnetic Resonance Imaging / methods

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20074963.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


36. Monleón D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortés O, Gil-Benso R, López-Ginés C, Cerdá-Nicolás M, Celda B: Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res; 2008 Jul;7(7):2882-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling.
  • Sometimes, meningiomas with histological diagnosis of benign meningioma show clinical characteristics of atypical meningioma.
  • In this work, we show differences between benign and atypical meningiomas in HR-MAS molecular profiles of meningioma biopsies.
  • Metabolic differences between meningioma grades include changes in the levels of glutathione.
  • Overall, this work suggests that the additional information obtained by NMR metabolomics applied to biopsies of human meningiomas may be useful for assessing tumor grade and determining optimum treatment strategies.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Principal Component Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507434.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Marton E, Bonaldi L, Busato S, Longatti P: Atypical meningioma in Werner syndrome: a case report. J Neurooncol; 2006 Sep;79(2):181-5
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical meningioma in Werner syndrome: a case report.
  • INTRODUCTION: Werner Syndrome, or adult progeria, is a rare autosomal recessive disorder caused by a mutation in the Werner Syndrome Gene belonging to the family of RecQ helicase.
  • CLINICAL PRESENTATION: We present the case of a 46-year-old man with Werner Syndrome and a convexity meningioma.
  • He underwent surgery with Simpson grade II removal, with improvement of the slight paresis and no other neurological defects.
  • Histological examination revealed an atypical meningioma.
  • CONCLUSION: 1p deletion correlates with meningioma progression and in this case correlates with histological examination.
  • [MeSH-major] Brain Neoplasms / complications. Chromosomes, Human, Pair 22 / genetics. Meningioma / complications. Monosomy / diagnosis. Werner Syndrome / complications

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Werner's syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598422.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


38. Milker-Zabel S, Zabel A, Schulz-Ertner D, Schlegel W, Wannenmacher M, Debus J: Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys; 2005 Mar 1;61(3):809-16
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors.
  • PURPOSE: To analyze our long-term experience and prognostic factors after fractionated stereotactic radiotherapy (FSRT) in patients with benign or atypical intracranial meningioma.
  • METHODS AND MATERIALS: Between January 1985 and December 2001, 317 patients with a median age of 55.7 years were treated with FSRT for intracranial meningioma.
  • The tumor distribution was World Health Organization (WHO) Grade 1 in 48.3%, WHO Grade 2 in 8.2%, and unknown in 43.5%.
  • Local tumor failure was significantly greater in patients with WHO Grade 2 meningioma (p <0.002) than in patients with WHO Grade 1 or unknown histologic features.
  • Patients treated for recurrent meningioma showed a trend toward decreased progression-free survival compared with patients treated with primary therapy, after biopsy, or after subtotal resection (p <0.06).
  • Eight patients developed new clinical symptoms, such as reduced vision, trigeminal neuralgia, and intermittent tinnitus located at the side of the irradiated meningioma after FSRT.
  • CONCLUSION: These data have demonstrated that FSRT is an effective and safe treatment modality for local control of meningioma with a low risk of significant late toxicity.
  • We identified the tumor volume, indication for FSRT, and histologic features of the meningioma as statistically significant prognostic factors.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease Progression. Dose Fractionation. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Prognosis. Radiotherapy Planning, Computer-Assisted. Stereotaxic Techniques. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708260.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Baxter DS, Smith P, Stewart K, Murphy M: Clear cell meningioma presenting as rapidly deteriorating visual field and acuity during pregnancy. J Clin Neurosci; 2009 Nov;16(11):1502-4
MedlinePlus Health Information. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell meningioma presenting as rapidly deteriorating visual field and acuity during pregnancy.
  • Clear cell meningioma is a rare histological phenotype of meningioma.
  • It has an atypical grade II World Health Organization classification due to a high recurrence rate.
  • [MeSH-major] Meningeal Neoplasms / complications. Meningioma / complications. Perceptual Disorders / etiology. Pregnancy / physiology. Visual Acuity / physiology. Visual Fields / physiology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging / methods

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632846.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


40. Kamide T, Nakada M, Hayashi Y, Suzuki T, Hayashi Y, Uchiyama N, Kijima T, Hamada J: Radiation-induced cerebellar high-grade glioma accompanied by meningioma and cavernoma 29 years after the treatment of medulloblastoma: a case report. J Neurooncol; 2010 Nov;100(2):299-303
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced cerebellar high-grade glioma accompanied by meningioma and cavernoma 29 years after the treatment of medulloblastoma: a case report.
  • Here, we report the case of a patient with cerebellar high-grade glioma that developed after the patient underwent treatment for medulloblastoma.
  • According to pathological examination, the tumor was a high-grade glioma that was positive for methylated O-6-methylguanine-DNA methyltransferase promoter.
  • [MeSH-major] Cerebellar Neoplasms / etiology. Glioma / etiology. Hemangioma, Cavernous, Central Nervous System / etiology. Meningioma / etiology. Meningioma / pathology. Neoplasms, Radiation-Induced / pathology
  • [MeSH-minor] Adult. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Humans. Male. Medulloblastoma / radiotherapy. Meningeal Neoplasms / etiology. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Polymerase Chain Reaction. Promoter Regions, Genetic / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Radiation induced meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354758.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


41. Ozen O, Demirhan B, Altinörs N: Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol; 2005 Sep-Oct;24(5):219-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
  • The aim of this study was to re-evaluate tumors diagnosed as meningioma previously in our hospital, according to the latest World Health Organization classification.
  • We also examined the relationships among parameters such as brain invasion, histological grade and Ki-67 and p53 expression in these tumors.
  • MATERIALS AND METHODS: Meningioma biopsy specimens numbering 60 (48 grade I, 11 grade II, and 1 grade III tumors) were examined immunohistochemically using monoclonal antibodies for Ki-67 (MIB-1) and p53 protein.
  • The mean MIB-1 LI values for the grade I and grade II tumors were 1.1% and 2.3%, respectively.
  • The MIB-1 LI and the level of p53 expression in the one grade III meningioma were 6.7% and 10 - 70%, respectively.
  • Histological grade was significantly correlated with MIB-1 LI and with p53 expression (p < 0.01 for both).
  • Brain invasion was not correlated with histological grade, MIB-1 LI, or p53 expression.
  • CONCLUSION: The results indicate that MIB-1 LI and p53 protein expression are good indicators of histological grade in meningioma and may be particularly valuable for distinguishing borderline atypical meningiomas.
  • The number of cases was limited, but the findings also suggest that brain invasion is a prognostic parameter independent of grade, MIB-1 LI and p53 expression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / biosynthesis. Meningeal Neoplasms / pathology. Meningioma / pathology. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167545.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


42. Engenhart-Cabillic R, Farhoud A, Sure U, Heinze S, Henzel M, Mennel HD, Bertalanffy H: Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment. Strahlenther Onkol; 2006 Nov;182(11):641-6
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
  • Patients with atypical meningioma received radiotherapy only for the recurrent disease.
  • Radiographic findings suggestive of aggressiveness were observed mostly with WHO grade III meningiomas.
  • By comparing the proliferation rate in four cases with atypical meningioma operated twice, the recurrent tumor had a higher proliferation rate than the first tumor in three cases.
  • There was no mortality among patients with atypical meningioma, while four out of five patients with anaplastic meningioma died during follow-up.
  • The peculiar focal expression patterns of anaplastic meningioma in MIB-1 might be a marker of such malignant development.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Biomarkers. Combined Modality Therapy. Dose Fractionation. Female. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Male. Meninges / pathology. Microsurgery. Middle Aged. Neoplasm Recurrence, Local. Practice Guidelines as Topic. Prognosis. Radiotherapy Dosage. Sex Factors. Stereotaxic Techniques. Survival Analysis. Time Factors. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17072521.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen
  •  go-up   go-down


43. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, Baio SM, Aricò D, Sansovini M, Paganelli G: Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging; 2009 Sep;36(9):1407-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.
  • However, for high-grade histotypes or partially resected tumours, recurrence is fairly common.
  • We assessed peptide receptor radionuclide therapy (PRRT) using (90)Y-DOTATOC in a group of patients with meningioma recurring after standard treatments in all of whom somatostatin receptors were strongly expressed on meningioma cell surfaces.
  • METHODS: Twenty-nine patients with scintigraphically proven somatostatin subtype 2 receptor-positive meningiomas were enrolled: 14 had benign (grade I), 9 had atypical (grade II) and 6 had malignant (grade III) disease.
  • Better results were obtained in patients with grade I meningioma than in those with grade II-III, with median time to progression (from beginning PRRT) of 61 months in the low-grade group and 13 months in the high-grade group.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Octreotide / analogs & derivatives. Radiopharmaceuticals / therapeutic use. Receptors, Somatostatin / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Young Adult. Yttrium Radioisotopes

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19319527.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 0 / Yttrium Radioisotopes; 0 / somatostatin receptor 2; RWM8CCW8GP / Octreotide; U194AS08HZ / Edotreotide
  •  go-up   go-down


44. Cecchi PC, Billio A, Colombetti V, Rizzo P, Ricci UM, Schwarz A: Primary high-grade B-cell lymphoma of the choroid plexus. Clin Neurol Neurosurg; 2008 Jan;110(1):75-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary high-grade B-cell lymphoma of the choroid plexus.
  • A brain MRI scan displayed an intraventricular lesion located in the right atrium, about 2.5cm in its major axis, homogeneously enhancing after gadolinium administration, surrounded by edema in the homolateral deep hemispheric region; the main diagnostic hypothesis was meningioma.
  • The histological diagnosis was of high-grade diffuse large B-cell lymphoma.
  • It usually occurs in the lateral ventricles (with a predilection for the atrium) of adult people (>50 years of age), apparently with a male prevalence.
  • Generally, the radiological picture mimics that of a meningioma, despite the fact that meningiomas usually reach a greater volume before clinical onset.
  • Low-grade marginal zone B-cell, T-cell and high-grade diffuse large B-cell (present case) forms have been described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928135.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


45. Rousselot C, Francois P, Jan M, Bergemer AM: [Report of seven cases of clear-cell meningioma and a literature review]. Ann Pathol; 2010 Apr;30(2):73-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Report of seven cases of clear-cell meningioma and a literature review].
  • AIMS: Clear cell meningioma (CCM) is a rare variant of meningioma, which is important to distinguish because of its aggressive behaviour.
  • CONCLUSION: Our study supports the fact that MCC course is less favourable than meningioma WHO grade I, even in the absence of anaplastic area, high mitotic activity, or necrosis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Astrocytoma / diagnosis. Child, Preschool. Diagnostic Errors. Ependymoma / diagnosis. Female. Humans. Keratins / analysis. Ki-67 Antigen / analysis. Male. Middle Aged. Mucin-1 / analysis. Neurofibromatosis 2 / diagnosis. Neurofibromatosis 2 / genetics. Neurofibromatosis 2 / pathology. Receptors, Progesterone / analysis. Retrospective Studies. S100 Proteins / analysis. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20451062.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Mucin-1; 0 / Neoplasm Proteins; 0 / Receptors, Progesterone; 0 / S100 Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 33
  •  go-up   go-down


46. Erman T, Hanta I, Haciyakupoğlu S, Zorludemir S, Zeren H, Göçer AI: Huge bilateral pulmonary and pleural metastasis from intracranial meningioma: a case report and review of the literature. J Neurooncol; 2005 Sep;74(2):179-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge bilateral pulmonary and pleural metastasis from intracranial meningioma: a case report and review of the literature.
  • A case of recurrent meningioma with atypical features and extracranial metastases is reported.
  • A 34-year-old female was operated in 1996, 2000, and 2002, and frontal parasagittal meningioma was extirpated.
  • Histological diagnoses of all the resected tumors were meningotheliomatous meningioma, WHO Grade I.
  • Histological diagnosis was reported as an atypical meningioma; meningotheliomatous type; WHO Grade II.
  • Cytopathology was consistent with malignant meningioma, metastasis from the patient's known intracranial meningioma.
  • We reviewed and discussed the histopathological features and mechanisms of metastasizing meningioma.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary. Pleural Neoplasms / secondary
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16193389.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


47. Estall V, Treece SJ, Jena R, Jefferies SJ, Burton KE, Parker RA, Burnet NG: Pattern of relapse after fractionated external beam radiotherapy for meningioma: experience from Addenbrooke's Hospital. Clin Oncol (R Coll Radiol); 2009 Dec;21(10):745-52
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of relapse after fractionated external beam radiotherapy for meningioma: experience from Addenbrooke's Hospital.
  • AIMS: Radiotherapy is an important treatment modality for meningioma.
  • We aimed to review the clinical outcomes for meningioma patients treated with radiotherapy in the Addenbrooke's Hospital Oncology Department.
  • MATERIALS AND METHODS: A retrospective chart review was carried out on patients with meningioma referred and treated in the department between 1 November 1996 and 31 October 2006.
  • Overall survival was 78% at the time of follow-up, with death related to meningioma in 7% of the total cohort.
  • Local control was 85% overall, 93% for grade 1 disease, 45% for grade 2 disease and 82% for grade 3 disease.
  • Patients with non-benign disease were more likely to receive >50Gy (27% of grade 1 lesions vs 65% of grade 2/3 lesions), but despite this local control remained poor, even with the higher dose delivered (local control 60 and 40% for grade 2 lesions treated with 50 and >50Gy, respectively, and 100 and 75% for grade 3 lesions treated with 50 and >50Gy, respectively).
  • Grade was an important prognostic factor.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hospitals. Humans. Male. Middle Aged. Radiotherapy / methods. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19783416.001).
  • [ISSN] 1433-2981
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


48. Jager B, Schuhmann MU, Schober R, Kortmann RD, Meixensberger J: Induction of gliosarcoma and atypical meningioma 13 years after radiotherapy of residual pilocytic astrocytoma in childhood. Pediatr Neurosurg; 2008;44(2):153-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of gliosarcoma and atypical meningioma 13 years after radiotherapy of residual pilocytic astrocytoma in childhood.
  • A local recurrence, grade WHO III, with signs of focal sarcomatous transformation, was subtotally resected 13 years later in 2001.
  • A new and fast growing right frontal meningioma, grade WHO II, was removed in 2003.
  • Irradiation-induced meningiomas in children are known to occur, however not following radiotherapy of low-grade hemispheric gliomas.
  • [MeSH-major] Astrocytoma / radiotherapy. Gliosarcoma / etiology. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Radiation-Induced / etiology
  • [MeSH-minor] Adult. Humans. Male. Radiotherapy / adverse effects


49. Goshen Y, Stark B, Kornreich L, Michowiz S, Feinmesser M, Yaniv I: High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Sep;49(3):294-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia.
  • Only one low-grade glioma and two basal-cell carcinomas were found.
  • Only one of the 74 non-irradiated patients (median follow-up 14 years) developed meningioma.
  • The Kaplan-Meier estimate of incidence of meningioma was 14.8+/-7.6 at 20 years.
  • [MeSH-major] Cranial Irradiation / adverse effects. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Neoplasms, Second Primary / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Humans. Incidence. Israel / epidemiology. Male


50. Kasuya H, Kubo O, Tanaka M, Amano K, Kato K, Hori T: Clinical and radiological features related to the growth potential of meningioma. Neurosurg Rev; 2006 Oct;29(4):293-6; discussion 296-7
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and radiological features related to the growth potential of meningioma.
  • Clinical and radiological features that help predict the growth potential of meningioma would be beneficial.
  • We analyzed the relationship of MIB-1 staining indices to characteristics of 342 consecutive patients with meningioma surgically removed between 1995 and 2004 by logistic regression analysis.
  • One hundred and forty-nine of the patients with meningioma were >or=60 in age; 89 male; 48 recurrent; 203 symptomatic; 157 at the skull base; 124 over 20 cm(3); 24 multiple; 136 with edema; 117 with calcification.
  • The MIB-1 staining index in 56 of 296 grade I meningiomas in WHO classification was >or= 3.0; in 27 of 28 grade II; and in 17 of 18 grade III, respectively.
  • [MeSH-major] Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Coloring Agents. Female. Humans. Ki-67 Antigen. Logistic Models. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Odds Ratio. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Jan;68(1):25-8 [10601396.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(5):507-11 [10898357.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] Neurosurg Rev. 2003 Jul;26(3):221-8 [12690530.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):209-14 [15072469.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] Surg Neurol. 1985 Aug;24(2):165-72 [4012573.001]
  • [Cites] Surg Neurol. 1987 Apr;27(4):319-22 [3824137.001]
  • [Cites] J Pathol. 1992 Dec;168(4):357-63 [1484317.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):222-4 [7616265.001]
  • [Cites] Neurosurgery. 1995 Dec;37(6):1049-55 [8584144.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):133-43 [8646709.001]
  • [Cites] Acta Neuropathol. 1996;91(5):504-10 [8740231.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(1):26-31; discussion 31-2 [9522904.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Cancer. 1999 May 15;85(10):2249-54 [10326705.001]
  • [Cites] In Vivo. 2004 Jul-Aug;18(4):411-6 [15369177.001]
  • (PMID = 16953450.001).
  • [ISSN] 0344-5607
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Ki-67 Antigen
  • [Other-IDs] NLM/ PMC1564192
  •  go-up   go-down


51. Lui PC, Chau TK, Wong SS, Lau PP, Tse GM, Thomas TM, Ng HK: Cytology of chordoid meningioma: a series of five cases with emphasis on differential diagnoses. J Clin Pathol; 2007 Sep;60(9):1024-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of chordoid meningioma: a series of five cases with emphasis on differential diagnoses.
  • BACKGROUND: Chordoid meningioma is a rare meningioma variant characterised by epithelioid cord-like tumour cells in a myxoid stroma.
  • It is classified as grade II (World Health Organization) tumours, as they have a tendency to behave more aggressively than traditional meningiomas and have a greater likelihood of recurrence.
  • AIMS: To report the features of intraoperative imprint smears of five cases of chordoid meningioma.
  • [MeSH-minor] Adult. Aged. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Intranuclear Inclusion Bodies / pathology. Intraoperative Care / methods. Magnetic Resonance Imaging. Male. Middle Aged. Vacuoles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):259-63 [15085764.001]
  • [Cites] Neurosurgery. 1991 Oct;29(4):575-9 [1944839.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Acta Cytol. 1994 May-Jun;38(3):331-4 [8191821.001]
  • [Cites] Acta Cytol. 1995 Jul-Aug;39(4):693-7 [7543235.001]
  • [Cites] Acta Cytol. 1998 May-Jun;42(3):614-8 [9622677.001]
  • [Cites] Acta Cytol. 1999 Mar-Apr;43(2):252-6 [10097720.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):454-8 [10470821.001]
  • [Cites] Clin Neuropathol. 2004 Sep-Oct;23(5):232-7 [15581026.001]
  • [Cites] Virchows Arch. 2005 Mar;446(3):333-7 [15714337.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):899-905 [10895812.001]
  • [Cites] Am J Surg Pathol. 2002 Oct;26(10):1330-42 [12360048.001]
  • [Cites] Arq Neuropsiquiatr. 2003 Mar;61(1):91-4 [12715027.001]
  • [Cites] Ann Pathol. 2003 Feb;23(1):76-8 [12743508.001]
  • [Cites] J Korean Med Sci. 2003 Oct;18(5):768-71 [14555838.001]
  • [Cites] Ultrastruct Pathol. 2003 Sep-Oct;27(5):363-8 [14708728.001]
  • [Cites] Neurol India. 2003 Dec;51(4):522-4 [14742937.001]
  • [Cites] Neuropathology. 2004 Sep;24(3):243-7 [15484703.001]
  • [Cites] Acta Cytol. 2004 May-Jun;48(3):397-401 [15192958.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):391-406 [3383139.001]
  • (PMID = 16837627.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1972413
  •  go-up   go-down


52. Dulai MS, Khan AM, Edwards MS, Vogel H: Intraventricular metaplastic meningioma in a child: case report and review of the literature. Neuropathology; 2009 Dec;29(6):708-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraventricular metaplastic meningioma in a child: case report and review of the literature.
  • Childhood meningiomas are rare and display important differences from adult forms.
  • We report the first case of an intraventricular metaplastic meningioma arising in a child.
  • Ultrastructural analysis demonstrated intermediate filaments, complex intercellular interdigitations and desmosomes, and a diagnosis of myxoid (metaplastic) meningioma was rendered.
  • Recognition of the grade I myxoid meningioma in this case is paramount since chordoid meningiomas, which share similar histologic features, are of a higher grade and worse prognosis.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Lateral Ventricles / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19389075.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


53. Hernández Faraco A, Céspedes G, Trejo E: [Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas]. Neurologia; 2009 May;24(4):235-44
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas].
  • The histological grade of the WHO and the extension of the initial surgical resection are determining prognostic factors in these tumors.
  • METHODS: A total of 93 cases were selected for the immunohistochemical study of the progesterone receptor (PR) in relation to the histological grade and the risk of recurrencies in meningiomas.
  • RESULTS: Though the immunohistochemical labelling index (LI) of the PR decreased with the progression of the histological grade (means of 27.37 % for grade I, 17.89% for grade II, and 13.50% for grade III), such correlation was not statistically significant and the cut off estimated in 20% was not satisfactory to discriminate among benign meningiomas (grade I) and non benign (grades II-III) due to its poor sensitivity (56.10%) and positive predictive value (56.10 %).
  • CONCLUSION: The LI of the PR is apparently not related to the histological grade of the meningiomas, but is significantly smaller in recurrent meningiomas.
  • A meningioma with a LI of the PR less than 40 % suggests the risk of recurrences.
  • [MeSH-major] Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. Receptors, Progesterone / biosynthesis
  • [MeSH-minor] Adult. Biomarkers, Tumor. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Risk Assessment. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19603293.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Progesterone
  •  go-up   go-down


54. Miao Y, Lu X, Qiu Y, Jiang J, Lin Y: A multivariate analysis of prognostic factors for health-related quality of life in patients with surgically managed meningioma. J Clin Neurosci; 2010 Apr;17(4):446-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multivariate analysis of prognostic factors for health-related quality of life in patients with surgically managed meningioma.
  • The objective of this study was to examine the prognostic significance of health-related quality of life (HQOL) parameters combined with baseline clinical factors in patients undergoing neurosurgery for treatment of meningioma.
  • A total of 147 patients (61 male, 86 female; mean age 43 years, range 5-77 years) who underwent resection of a meningioma between January 2002 and December 2004 were studied.
  • The relationships between HQOL and clinical history, radiological findings, extent of resection, histological grade and recurrence were investigated using multivariate analysis.
  • The mean HQOL score was 73.94+/-1.79 for preoperative patients with meningioma, 84.88+/-2.14 for postoperative patients, and 91.13+/-1.61 for healthy controls.
  • HQOL for patients with meningioma was significantly lower than that for normal controls (P<0.001), and postoperative patients had a more satisfactory HQOL than preoperative (P<0.05).
  • Cox proportional hazards analysis showed that significant predictors of health-related quality of life were tumor size, extent of surgical excision, and histologic grade.
  • Multivariate backward logistic regression yielded the regression equation HQOL=119.1097 - 1.5002X(3) - 8.6650X(6) - 10.4210X(7) (R=0.7466; where X(3) is tumor size, X(6) is extent of surgical excision, and X(7) is the histologic grade of the tumor).
  • This equation can be used preoperatively to predict the HQOL of meningioma patients after neurosurgery.
  • A specialized HQOL questionnaire for patients with meningioma provides useful information when planning the operative procedure, and may make it more likely that patients have a satisfactory HQOL after surgery.
  • [MeSH-major] Health Status Indicators. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Prognosis. Quality of Life. Surveys and Questionnaires. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 20138525.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


55. Zhi L, Bing L, Yang L, Bo-ning L, Quan H: Cystic papillary meningioma with subarachnoid dissemination: a case report and review of the literature. Pathol Res Pract; 2009;205(8):582-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic papillary meningioma with subarachnoid dissemination: a case report and review of the literature.
  • Meningiomas usually present as benign tumors corresponding to WHO grade I.
  • We report a case of cystic papillary meningioma in a young female occurring in the lateral ventricle with invasion of brain parenchyma and dissemination of subarachnoid space.
  • The tumor exhibits a marked peritumoral cyst, with contrast enhancement on magnetic resonance imaging (MRI) in accordance with type 2 of Zee's classification of cystic meningioma.
  • A diagnosis of primary intraventricular cystic papillary meningioma with subarachnoid space dissemination (WHO grade III) was made.
  • To our knowledge, there is no report describing the radiological and histological characteristics of cystic papillary meningioma presenting in the lateral ventricle.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Cysts / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Magnetic Resonance Imaging. Mucin-1 / metabolism. Neoplasm Staging. Treatment Outcome. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307065.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Vimentin
  •  go-up   go-down


56. Chacko JG, Miller JL, Angtuaco EJ: Spontaneous postpartum resolution of vision loss caused by a progesterone receptor-positive tuberculum sellae meningioma. J Neuroophthalmol; 2010 Jun;30(2):132-4
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous postpartum resolution of vision loss caused by a progesterone receptor-positive tuberculum sellae meningioma.
  • Brain MRI disclosed an intracranial mass compressing the optic nerves and chiasm with imaging features suggestive of meningioma.
  • It was a grade I meningioma with progesterone cell surface receptors.
  • This is the first reported case with full visual function and MRI documentation of spontaneous postpartum visual recovery in a progesterone receptor-positive meningioma compressing the anterior visual pathway.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis. Receptors, Progesterone / metabolism. Sella Turcica / pathology. Vision, Low / etiology. Visual Pathways / pathology
  • [MeSH-minor] Adult. Craniotomy. Decompression, Surgical. Female. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures. Optic Chiasm / pathology. Optic Chiasm / physiopathology. Optic Nerve / pathology. Optic Nerve / physiopathology. Pregnancy / physiology. Pregnancy Complications / metabolism. Pregnancy Complications / physiopathology. Progesterone / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20393348.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Progesterone; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


57. Smith JS, Quiñones-Hinojosa A, Harmon-Smith M, Bollen AW, McDermott MW: Sex steroid and growth factor profile of a meningioma associated with pregnancy. Can J Neurol Sci; 2005 Feb;32(1):122-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex steroid and growth factor profile of a meningioma associated with pregnancy.
  • METHODS: We describe the presentation of a meningioma during the immediate postpartum period.
  • RESULTS: The lesion proved to be an atypical fibroblastic meningioma grade II (WHO).
  • CONCLUSION: Although clinical regression of meningioma following pregnancy is well-recognized, imaging data are much less abundant.
  • This report provides clear clinical and imaging documentation of a meningioma associated with pregnancy.
  • [MeSH-major] Growth Substances / metabolism. Meningeal Neoplasms / pathology. Meningioma / pathology. Pregnancy Complications. Receptors, Steroid / metabolism
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Placental Lactogen / metabolism. Postpartum Period. Pregnancy. Proto-Oncogene Proteins c-sis / metabolism. Receptor Protein-Tyrosine Kinases / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptor, Fibroblast Growth Factor, Type 2. Receptors, Estrogen / metabolism. Receptors, Fibroblast Growth Factor / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825560.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Growth Substances; 0 / Proto-Oncogene Proteins c-sis; 0 / Receptors, Estrogen; 0 / Receptors, Fibroblast Growth Factor; 0 / Receptors, Progesterone; 0 / Receptors, Steroid; 9035-54-5 / Placental Lactogen; EC 2.7.10.1 / FGFR2 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2
  •  go-up   go-down


58. Willis J, Smith C, Ironside JW, Erridge S, Whittle IR, Everington D: The accuracy of meningioma grading: a 10-year retrospective audit. Neuropathol Appl Neurobiol; 2005 Apr;31(2):141-9
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy of meningioma grading: a 10-year retrospective audit.
  • Although descriptive classifications of meningioma subtypes are well established, there has been inconsistency in the categorization of meningiomas into benign, atypical and anaplastic groups.
  • The aim of this study was to reassess the incidence of atypical (grade II) meningiomas over a 10-year period by applying the World Health Organization (WHO) 2000 classification system.
  • A secondary aim was to determine if grade II and III tumours were becoming more common.
  • On reclassification, 78% of the meningiomas were classified as grade I, 20.4% as grade II and 1.6% as grade III.
  • With regard to grade II meningiomas classified by using the WHO 2000 classification system, 38.1% had originally been classified as grade I prior to 2000, whereas 13.6% had originally been classified as grade I after 2000.
  • [MeSH-major] Meningeal Neoplasms / classification. Meningeal Neoplasms / pathology. Meningioma / classification. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Reproducibility of Results. Retrospective Studies. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771707.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Schmid S, Aboul-Enein F, Pfisterer W, Birkner T, Stadek C, Knosp E: Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients. Neurosurgery; 2010 Dec;67(6):1703-8; discussion 1708
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor: the major factor for tumor neovascularization and edema formation in meningioma patients.
  • BACKGROUND: Peritumoral brain edema (PTBE) may be crucial in the clinical outcome of meningioma patients.
  • OBJECTIVE: As PTBE formation is widely accepted to be vasogenic, we investigated the role of vascular endothelial growth factor (VEGF) and pial supplying vessels in a series of World Health Organization (WHO) grade I meningiomas.
  • METHODS: A total of 79 patients with WHO grade I meningiomas were immunohistochemically studied for VEGF and MIB-1.
  • RESULTS: VEGF was found to be exclusively confined to meningioma tumor cells.
  • VEGF and supplying pial vessels were found in 14 meningioma patients, pial vascular supply only in 3, VEGF expression only in 46, and neither VEGF expression nor supplying pial vessels in 16.
  • CONCLUSION: Our data suggest that VEGF may be crucial in angiogenesis and therefore indirectly in PTBE formation in World Health Organization grade I meningiomas.
  • [MeSH-major] Brain Edema / etiology. Gene Expression Regulation, Neoplastic / physiology. Meningeal Neoplasms / complications. Meningioma / complications. Neovascularization, Pathologic / etiology. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Regression Analysis. Statistics, Nonparametric. Young Adult

  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21107201.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


60. Chen YY, Tiang XY, Li Z, Luo BN, Huang Q: Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature. Diagn Pathol; 2010;5:39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic meningioangiomatosis-associated atypical meningioma mimicking parenchymal invasion of brain: a case report and review of the literature.
  • In extremely rare condition, meningioma may occur together with meningioangiomatosis, and only 19 cases have been described in English literature until now.
  • We now report a case of meningioangiomatosis-associated meningioma with atypical and clear cell variant.
  • Microscopically, parts of lesions were atypical and clear cell meningioma corresponding to WHO grade II.
  • Neoplastic cells in atypical meningioma area were immunoreactive to epithelial membrane antigen (EMA) with high MIB-1 index of up to 20%.
  • The diagnosis of atypical meningioma associated with sporadic meningioangiomatosis was made.
  • To our knowledge, this is the first case of a meningioangiomatosis-associated meningioma with atypical and clear cell variant component to be described.
  • Meningioangiomatosis-associated meningioma is more likely to occur in younger patients and histologically to mimic parenchymal invasion of brain.
  • We suggest that postoperative radiotherapy or chemotherapy should be given careful consideration to avoid over-treatment due to erroneously interpret as malignant meningioma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Central Nervous System Vascular Malformations / diagnosis. Cerebral Cortex / pathology. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2000 Apr;92(4):706-10 [10761664.001]
  • [Cites] Acta Cytol. 2009 Jan-Feb;53(1):93-7 [19248561.001]
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):568-72 [11826364.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):48-56 [11849563.001]
  • [Cites] Nervenarzt. 2002 Oct;73(10):990-4 [12376888.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Apr;29(2):170-4 [12662324.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):643-5 [14655769.001]
  • [Cites] Am J Clin Pathol. 1974 Oct;62(4):481-7 [4212953.001]
  • [Cites] J Neurosurg. 1982 Jan;56(1):154-7 [7054414.001]
  • [Cites] Acta Neuropathol. 1987;73(4):361-4 [3618128.001]
  • [Cites] J Neurosurg. 1990 Nov;73(5):715-9 [2213161.001]
  • [Cites] Pathol Res Pract. 1992 Feb;188(1-2):145-7 [1594484.001]
  • [Cites] J Neurosurg. 1993 Feb;78(2):287-9 [8421212.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):485-9 [9143261.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):872-5 [10435554.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Childs Nerv Syst. 2006 Jan;22(1):78-83 [16389566.001]
  • [Cites] Surg Neurol. 2006 Jun;65(6):595-603 [16720184.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):125-9 [11756780.001]
  • (PMID = 20565869.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2904739
  •  go-up   go-down


61. Lin JW, Ho JT, Lin YJ, Wu YT: Chordoid meningioma: a clinicopathologic study of 11 cases at a single institution. J Neurooncol; 2010 Dec;100(3):465-73
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chordoid meningioma: a clinicopathologic study of 11 cases at a single institution.
  • Chordoid meningioma is an uncommon variant of meningioma, which histologically bears a great resemblance to chordoma and often follows an aggressive clinical course.
  • Thirteen specimens of chordoid meningioma belonging to 11 patients were obtained at a single institution from 1995 to 2009.
  • Six tumors (46%) were classified as benign (grade I) and seven tumors (54%) atypical (grade II), if based solely on histologic grading irrespective of chordoid or clear cell components in our cases.
  • [MeSH-major] Choroid Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD / metabolism. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Mucin-1 / metabolism. Retrospective Studies. Taiwan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurooncol. 2011 Aug;104(1):395-7 [21136280.001]
  • (PMID = 20454999.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Ki-67 Antigen; 0 / Mucin-1
  •  go-up   go-down


62. Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, Lin CK, Yen CH, Chen JH, Lin GJ, Ma HI, Yeh YS, Ju DT, Liu MY, Hueng DY: Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol; 2010 Nov;100(2):217-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas.
  • Prediction of recurrence remains a challenge in histopathological benign/grade I tumors.
  • Our results showed that meningioma recurrence correlated significantly with OPN IHC score (P = 0.001).
  • We concluded that OPN IHC score may play a role in prediction of the recurrence of the grade I meningiomas.
  • Moreover, determination of the OPN Allred score is a reliable, quantitative tool for predicting recurrence-free time in benign meningioma patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology. Osteopontin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Tissue Array Analysis. World Health Organization. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428925.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SPP1 protein, human; 106441-73-0 / Osteopontin
  •  go-up   go-down


63. Tong-tong W, Li-juan B, Zhi L, Yang L, Bo-ning L, Quan H: Clear cell meningioma with anaplastic features: case report and review of literature. Pathol Res Pract; 2010 May 15;206(5):349-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell meningioma with anaplastic features: case report and review of literature.
  • Clear cell meningioma (CCM) is an uncommon variant of meningioma, corresponding to WHO grade II.
  • A diagnosis of CCM with anaplastic features was made (WHO grade III).
  • [MeSH-major] Frontal Lobe / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Anaplasia / pathology. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009. Published by Elsevier GmbH. All rights reserved.
  • (PMID = 19857933.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


64. Cramer P, Thomale UW, Okuducu AF, Lemke AJ, Stockhammer F, Woiciechowsky C: An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report. J Neurosurg Spine; 2005 Aug;3(2):153-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An atypical spinal meningioma with CSF metastasis: fatal progression despite aggressive treatment. Case report.
  • Following intraspinal decompression the tumor was histologically classified as an atypical meningioma (World Health Organization grade II).
  • Two further surgical interventions resulted in almost total removal of the meningioma.
  • The results in the reported case indicate that meningiomas associated with cerebrospinal fluid metastasis may represent a higher grade of malignancy.
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cervical Vertebrae. Decompression, Surgical. Disease Progression. Fatal Outcome. Humans. Hydroxyurea / therapeutic use. Joint Instability / etiology. Magnetic Resonance Imaging. Male. Myelography. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neurosurgical Procedures / adverse effects. Radiotherapy, Adjuvant. Reoperation. Spinal Diseases / etiology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Meningioma, spinal.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16370305.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


65. Jouanneau E, Guzman Tovar RA, Desuzinges C, Frappaz D, Louis-Tisserand G, Sunyach MP, Jouvet A, Sindou M: Very late frontal relapse of medulloblastoma mimicking a meningioma in an adult: usefulness of 1H magnetic resonance spectroscopy and diffusion-perfusion magnetic resonance imaging for preoperative diagnosis: case report. Neurosurgery; 2006 Apr;58(4):E789; discussion E789
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very late frontal relapse of medulloblastoma mimicking a meningioma in an adult: usefulness of 1H magnetic resonance spectroscopy and diffusion-perfusion magnetic resonance imaging for preoperative diagnosis: case report.
  • OBJECTIVE AND IMPORTANCE: We present a rare case of very long-term medulloblastoma relapse in an adult patient and discuss the pattern of recurrence and metabolic imaging of the tumor.
  • Magnetic resonance images were suggestive of a meningioma.
  • Several hypotheses were discussed, such as other radio-induced tumors, sarcomas, high-grade gliomas, or lymphomas (previous chemotherapy) and even recurrence of medulloblastoma.
  • Metabolic imaging favored the diagnosis of medulloblastoma over the initially suspected diagnosis of meningioma.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Medulloblastoma / diagnosis. Meningeal Neoplasms / diagnosis. Meningioma / diagnosis

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575298.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


66. Liu RS, Chang CP, Guo WY, Pan DH, Ho DM, Chang CW, Yang BH, Wu LC, Yeh SH: 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery. J Nucl Med; 2010 Jun;51(6):883-91
Hazardous Substances Data Bank. CARBON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery.
  • METHODS: Twenty-two patients with the neuroradiologic diagnosis of meningioma were examined by 1-(11)C-acetate and (18)F-FDG PET on the same day.
  • There were 12 cases of histopathologically proven meningioma (8 grade I, 2 grade II, and 2 grade III), 1 of tuberculous granuloma, and 1 of degenerative tissue.
  • RESULTS: The (18)F-FDG PET study revealed a hypometabolic focus in 17 meningiomas (8 grade I, 1 grade II, and 8 unknown grade) and hypermetabolism in 1 grade II and 2 grade III meningiomas.
  • The standardized uptake value for 1-(11)C-acetate was not different from that for (18)F-FDG (mean +/- SD, 3.16 +/- 1.75 vs. 3.22 +/- 1.50, P = 0.601), but the tumor-to-cortex ratio for 1-(11)C-acetate was higher than that for (18)F-FDG (3.46 +/- 1.38 vs. 0.93 +/- 1.08, P < 0.005). (18)F-FDG was able to differentiate grade I from grade II-III meningiomas, whereas 1-(11)C-acetate was unable to do so.
  • Tuberculous granuloma had a high 1-(11)C-acetate and (18)F-FDG uptake similar to that of grade II/III meningioma.
  • However, 1-(11)C-acetate was not useful for evaluating the tumor grade. (18)F-FDG was found to be less useful than 1-(11)C-acetate for evaluating the extent of meningiomas and the response to radiosurgical treatment but may be useful for differentiating benign from malignant meningiomas. (18)F-FDG and 1-(11)C-acetate are complementary for assessing diverse cell metabolism of meningioma.
  • [MeSH-major] Acetates. Carbon. Fluorodeoxyglucose F18. Meningioma / radionuclide imaging. Meningioma / surgery. Positron-Emission Tomography / methods. Radiosurgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biological Transport. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Regression Analysis. Retrospective Studies. Treatment Outcome. Tumor Burden

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20484430.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetates; 0 / carbon-11 acetate; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7440-44-0 / Carbon
  •  go-up   go-down


67. Noël G, Bollet MA, Calugaru V, Feuvret L, Haie-Meder C, Dhermain F, Ferrand R, Boisserie G, Beaudré A, Mazeron JJ, Habrand JL: Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons. Int J Radiat Oncol Biol Phys; 2005 Aug 1;62(5):1412-22
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons.
  • Pathology revealed a malignant (Grade 3) transformation of the initial Grade 1 meningioma.
  • Two patients complained of Grade 3 side effects: 1 unilateral hearing loss requiring aid and 1 case of complete pituitary deficiency.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningioma / radiotherapy. Photons / therapeutic use. Protons / therapeutic use. Radiotherapy, Conformal / methods. Visual Acuity
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Dose Fractionation. Exophthalmos / radiotherapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029801.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


68. Jo K, Park HJ, Nam DH, Lee JI, Kong DS, Park K, Kim JH: Treatment of atypical meningioma. J Clin Neurosci; 2010 Nov;17(11):1362-6
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of atypical meningioma.
  • Radical extirpation surgery (Simpson grade I) was performed in 11 (31%) patients, and there was no tumor recurrence for these patients.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery. Neurosurgical Procedures / methods. Radiotherapy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20800497.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  •  go-up   go-down


69. Zhang MX, Zhao X, Wang ZG, Zhao WM, Wang YS: Constitutive activation of signal transducer and activator of transcription 3 regulates expression of vascular endothelial growth factor in human meningioma differentiation. J Cancer Res Clin Oncol; 2010 Jul;136(7):981-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive activation of signal transducer and activator of transcription 3 regulates expression of vascular endothelial growth factor in human meningioma differentiation.
  • The function of STAT3 in the pathogenesis of meningioma remains unknown.
  • In this study, we investigated the role of JAK1/STAT3 regulating vascular endothelial growth factor (VEGF) expression in the occurrence and progression of human meningioma.
  • METHODS: We detected the expression of JAK1, p-JAK1, STAT3, p-STAT3, and VEGF in human meningioma and normal dura tissues by RT-PCR, Western blot analysis, and immunohistochemistry.
  • RESULTS: JAK1, p-JAK1, STAT3, p-STAT3, and VEGF showed high expression in grade I and grade II meningioma.
  • The level of STAT3 activation was associated with VEGF expression; all meningioma tumors that expressed p-STAT3 also expressed VEGF.
  • Both frequency of positivity and expression were enhanced with increasing tumor grade; high frequencies and levels were found in grade II tumors, with no expression detected in normal dura tissues (P < 0.05).
  • CONCLUSIONS: VEGF is directly regulated by constitutive STAT3 activity and associated with meningioma differentiation.
  • STAT3 has an important role in the occurrence and development of human meningioma by regulating VEGF expression.
  • [MeSH-major] Janus Kinase 1 / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. STAT3 Transcription Factor / metabolism. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Blotting, Western. Disease Progression. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Sep 15;84(6):1760-4 [7521688.001]
  • [Cites] J Clin Invest. 1993 Jan;91(1):153-9 [8380810.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):811-20 [8642285.001]
  • [Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3801-4 [9108058.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):21872-7 [9268319.001]
  • [Cites] Cell. 1998 May 1;93(3):373-83 [9590172.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2381-7 [9703883.001]
  • [Cites] Clin Cancer Res. 1996 Aug;2(8):1411-6 [9816315.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Stem Cells. 1999;17(3):138-46 [10342556.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):440-6 [10470819.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):202-13 [15688401.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):371-7 [15949234.001]
  • [Cites] Histol Histopathol. 2005 Oct;20(4):1173-7 [16136500.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):171-9 [16846476.001]
  • [Cites] Brain Res. 2006 Jul 7;1098(1):26-32 [16764840.001]
  • [Cites] Br J Cancer. 2007 Aug 6;97(3):378-83 [17595657.001]
  • [Cites] Oncogene. 2008 Mar 6;27(11):1511-9 [17873904.001]
  • [Cites] Oncol Rep. 2008 Dec;20(6):1321-7 [19020709.001]
  • [Cites] Cancer Biol Ther. 2008 Dec;7(12):1994-2003 [18981713.001]
  • [Cites] PLoS One. 2009;4(5):e5578 [19440292.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Laryngoscope. 2000 May;110(5 Pt 1):868-74 [10807365.001]
  • [Cites] Int J Dev Neurosci. 2000 Jul-Aug;18(4-5):439-46 [10817928.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24935-44 [10823829.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):327-34 [11310826.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6613-26 [11426647.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6):536-42 [11740806.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2058-65 [11960378.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):319-29 [12545153.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] J Immunol. 2003 Oct 1;171(7):3863-71 [14500688.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):941-51 [15184909.001]
  • [Cites] EMBO J. 1995 Apr 3;14(7):1421-9 [7537214.001]
  • (PMID = 20052595.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.010.2 / JAK1 protein, human; EC 2.7.10.2 / Janus Kinase 1
  • [Other-IDs] NLM/ PMC2874489
  •  go-up   go-down


70. Martínez C, Molina JA, Alonso-Navarro H, Jiménez-Jiménez FJ, Agúndez JA, García-Martín E: Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol; 2010;10:71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma.
  • Aiming to identify genetic variations related to the risk of developing brain tumors, we investigated the putative association between common nonsynonymous PON1 polymorphisms and the risk of developing astrocytoma and meningioma.
  • METHODS: Seventy one consecutive patients with brain tumors (43 with astrocytoma grade II/III and 28 with meningioma) with ages ranging 21 to 76 years, and 220 healthy controls subjects were analyzed for the frequency of the nonsynonymous PON1 genotypes L55M rs854560 and Q192R rs662.
  • All participants were adult Caucasian individuals recruited in the central area of Spain.
  • RESULTS: The frequencies of the PON1 genotypes and allelic variants of the polymorphisms PON1 L55M and PON1 Q192R did not differ significantly between patients with astrocytoma and meningioma and controls.
  • The minor allele frequencies were as follows: PON1 55L, 0.398, 0.328 and 0.286 for patients with astrocytoma, meningioma and control individuals, respectively; PON1 192R, 0.341, 0.362 and 0.302 for patients with astrocytoma, meningioma and control individuals, respectively.
  • Haplotype association analyses did not identify any significant association with the risk of developing astrocytoma or meningioma.
  • CONCLUSIONS: Common nonsynonymous PON1 polymorphisms are not related with the risk of developing astrocytoma and meningioma.
  • [MeSH-major] Aryldialkylphosphatase / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics
  • [MeSH-minor] Adult. Aged. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single Nucleotide. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 1998 Sep;34(3):252-60 [9698994.001]
  • [Cites] Atherosclerosis. 1998 Aug;139(2):341-9 [9712341.001]
  • [Cites] Biochem Pharmacol. 1998 Sep 1;56(5):547-51 [9783722.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):116-25 [15386358.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Environ Health Perspect. 2005 May;113(5):546-51 [15866761.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):909-13 [16002382.001]
  • [Cites] Liver Int. 2005 Oct;25(5):935-9 [16162149.001]
  • [Cites] Toxicology. 2005 Nov 15;215(3):182-90 [16102884.001]
  • [Cites] Occup Environ Med. 2005 Nov;62(11):786-92 [16234405.001]
  • [Cites] World J Gastroenterol. 2006 Jan 28;12(4):615-20 [16489678.001]
  • [Cites] Acta Neurol Scand. 2006 May;113(5):322-6 [16629768.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1513-6 [16685388.001]
  • [Cites] Pharmacogenomics. 2006 Jul;7(5):711-8 [16886896.001]
  • [Cites] Cell Biochem Funct. 2006 Sep-Oct;24(5):455-60 [16142697.001]
  • [Cites] J Agric Saf Health. 2006 Nov;12(4):255-74 [17131948.001]
  • [Cites] Drug Metab Dispos. 2007 Feb;35(2):315-20 [17132760.001]
  • [Cites] Occup Environ Med. 2007 Aug;64(8):509-14 [17537748.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):559-75 [17701901.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2007 Jan-Mar;10(1-2):81-99 [18074305.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jan;18(1):37-43 [18216720.001]
  • [Cites] Am J Epidemiol. 2008 Apr 15;167(8):976-85 [18299277.001]
  • [Cites] Clin Chem. 2008 Aug;54(8):1390-4 [18664443.001]
  • [Cites] Curr Drug Metab. 2008 Jul;9(6):520-31 [18680472.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):709-15 [18682580.001]
  • [Cites] Psychiatr Genet. 2008 Dec;18(6):289-94 [19018234.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Apr 15;236(2):142-53 [19371602.001]
  • [Cites] Cell Biochem Funct. 2009 Dec;27(8):558-67 [19902425.001]
  • [Cites] Environ Health Perspect. 2010 Jan;118(1):144-9 [20056567.001]
  • [Cites] Adv Exp Med Biol. 2010;660:47-60 [20221870.001]
  • [Cites] Eur J Neurol. 2010 Jun 1;17(6):879-81 [20050883.001]
  • [Cites] Chem Biol Interact. 2010 Sep 6;187(1-3):355-61 [20338154.001]
  • [Cites] Neuromolecular Med. 2010 Sep;12(3):217-23 [19826962.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Feb;45(1):15-23 [10099836.001]
  • [Cites] Pharmacogenetics. 2000 Dec;10(9):767-79 [11191881.001]
  • [Cites] J Lipid Res. 2001 Apr;42(4):528-35 [11290824.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 15;173(1):1-6 [11350209.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1323-6 [11470765.001]
  • [Cites] Environ Health Perspect. 2001 Sep;109(9):909-13 [11673119.001]
  • [Cites] Ann Diagn Pathol. 2002 Feb;6(1):44-8 [11842378.001]
  • [Cites] Curr Opin Lipidol. 2002 Aug;13(4):357-62 [12151850.001]
  • [Cites] Am J Ind Med. 2002 Sep;42(3):214-27 [12210690.001]
  • [Cites] Cancer Causes Control. 2003 Mar;14(2):139-50 [12749719.001]
  • [Cites] Br J Neurosurg. 2003 Apr;17(2):182-4 [12820764.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1162-9 [14574645.001]
  • [Cites] J Mol Med (Berl). 2003 Dec;81(12):766-79 [14551701.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Am J Ind Med. 2004 May;45(5):395-407 [15095422.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Arch Pathol Lab Med. 1979 Dec;103(13):676-9 [583126.001]
  • [Cites] J Neurol. 1982;227(3):165-9 [6181224.001]
  • [Cites] Indian J Cancer. 1983 Mar;20(1A):86-8 [6873998.001]
  • [Cites] Am J Epidemiol. 1988 Oct;128(4):778-85 [3421243.001]
  • [Cites] Neurologia. 1988 Mar-Apr;3(2):68-70 [2856211.001]
  • [Cites] J Neurosci Nurs. 1992 Oct;24(5):260-4 [1328422.001]
  • [Cites] Am J Hum Genet. 1993 Mar;52(3):598-608 [7916578.001]
  • [Cites] Nat Genet. 1993 Jan;3(1):73-6 [8098250.001]
  • [Cites] Neurosurgery. 1995 Mar;36(3):599-604; discussion 604-5 [7753363.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4237-9 [7671227.001]
  • [Cites] J Neurosurg Sci. 1995 Mar;39(1):27-35 [8568553.001]
  • [Cites] Epidemiol Rev. 1995;17(2):382-414 [8654518.001]
  • [Cites] Curr Opin Lipidol. 1996 Apr;7(2):69-76 [8743898.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):334-6 [8896566.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Nature. 1998 Jul 16;394(6690):284-7 [9685159.001]
  • (PMID = 20723250.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.8.1 / Aryldialkylphosphatase; EC 3.1.8.1 / PON1 protein, human
  • [Other-IDs] NLM/ PMC2936881
  •  go-up   go-down


71. Pfisterer WK, Hendricks WP, Scheck AC, Nieman RA, Birkner TH, Krampla WW, Preul MC: Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas? Neurosurgery; 2007 Nov;61(5):1048-59; discussion 1060-1
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescent in situ hybridization and ex vivo 1H magnetic resonance spectroscopic examinations of meningioma tumor tissue: is it possible to identify a clinically-aggressive subset of benign meningiomas?
  • OBJECTIVE: Although histologically benign, Grade I meningiomas can sometimes behave aggressively.
  • The clinically-aggressive subset of Grade I meningiomas is typically indistinguishable from clinically-benign Grade I meningiomas in vivo.
  • We compared molecular genetic and biochemical findings to clinical, pathological, and immunohistochemical information in a series of clinically-aggressive Grade I meningiomas with a series of clinically-benign meningiomas to identify characteristics that may be used to distinguish between these two groups.
  • METHODS: Tumor tissue samples from 30 patients with Grade I meningiomas were harvested.
  • RESULTS: Molecular genetic and biochemical findings correlated with clinical behavior of the two Grade I meningioma groups.
  • The presence of aberrations also influenced meningioma regrowth after subtotal resection.
  • CONCLUSION: Distinct molecular genetic and biochemical alterations differentiated clinically-aggressive Grade I meningiomas from clinically-benign Grade I meningiomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. In Situ Hybridization, Fluorescence / methods. Magnetic Resonance Spectroscopy / methods. Meningioma / diagnosis. Meningioma / physiopathology. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Genetic Predisposition to Disease / genetics. Humans. Male. Middle Aged. Protons. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091281.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Protons
  •  go-up   go-down


72. Kafadar AM, Ergen A, Zeybek U, Agachan B, Kuday C, Isbir T: Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and meningiomas. Cell Biochem Funct; 2006 Sep-Oct;24(5):455-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraoxonase 192 gene polymorphism and serum paraoxonase activity in high grade gliomas and meningiomas.
  • The distribution of PON 192 polymorphism in 42 high grade gliomas and 42 meningiomas were determined by polymerase chain reaction--based restriction fragment length polymorphism analysis and compared with 50 healthy control subjects.
  • We found that in both tumour groups serum PON1 activity was significantly lower than the control group (p < 0.001), but did not differ between meningiomas and high grade gliomas.
  • [MeSH-major] Aryldialkylphosphatase / genetics. Brain Neoplasms / genetics. Glioma / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics
  • [MeSH-minor] Adult. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Genotype. Humans. Lipid Peroxidation. Male. Middle Aged. Polymorphism, Genetic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142697.001).
  • [ISSN] 0263-6484
  • [Journal-full-title] Cell biochemistry and function
  • [ISO-abbreviation] Cell Biochem. Funct.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.8.1 / Aryldialkylphosphatase; EC 3.1.8.1 / PON1 protein, human
  •  go-up   go-down


73. Hankins GR, Sasaki T, Lieu AS, Saulle D, Karimi K, Li JZ, Helm GA: Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor. Neurosurgery; 2008 Oct;63(4):771-80; discussion 780-1
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the deleted in liver cancer 1 gene, DLC1, as a candidate meningioma tumor suppressor.
  • To investigate the molecular mechanisms of meningioma formation, the expression profiles of 12 000 genes from meningiomas and dural specimens were compared.
  • METHODS: Ribonucleic acid from 6 meningiomas (World Health Organization Grade I) and 4 dural specimens was profiled using U95A GeneChips (Affymetrix, Inc., Santa Clara, CA).
  • Function and methylation of DLC1 were assessed by ectopic expression in 5 primary cultures, demethylation assay using 5-aza-2'-deoxycytidine, and methylation-specific polymerase chain reaction in 4 meningioma samples.
  • Although demethylation decreased meningioma cell growth rates in vitro, methylation-specific polymerase chain reaction did not detect DLC1 promoter methylation.
  • [MeSH-major] Meningioma / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenoviridae / genetics. Adult. Aged. Aged, 80 and over. Cell Proliferation. DNA Methylation / genetics. Down-Regulation. Dura Mater / metabolism. Female. GTPase-Activating Proteins. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Gene Transfer Techniques. Genetic Vectors / genetics. Humans. Male. Middle Aged. Promoter Regions, Genetic / genetics

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981889.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR016477
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DLC1 protein, human; 0 / GTPase-Activating Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


74. Milker-Zabel S, Zabel-du Bois A, Huber P, Schlegel W, Debus J: Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. Int J Radiat Oncol Biol Phys; 2007 Jul 1;68(3):858-63
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution.
  • PURPOSE: We analyzed our long-term experience with intensity-modulated radiotherapy (IMRT) in patients with complex-shaped meningioma of the skull base.
  • PATIENTS AND METHODS: Between January 1998 and December 2004, 94 patients with complex-shaped meningioma were treated using IMRT at our institution.
  • Tumor distribution was: World Health Organization (WHO) Grade 1 in 54.3%, WHO Grade 2 in 9.6%, and WHO Grade 3 in 4.2%.
  • In 31.9% of patients, the clinical and radiologic characteristics of the tumor were consistent with the diagnosis of meningioma.
  • Treatment-induced loss of vision was seen in 1 of 53 reirradiated patients with a Grade 3 meningioma 9 months after retreatment with IMRT.
  • CONCLUSION: These data demonstrate that IMRT is an effective and safe treatment modality for long-term local control of complex-shaped and otherwise difficult to treat meningioma.
  • [MeSH-major] Meningeal Neoplasms / mortality. Meningeal Neoplasms / radiotherapy. Meningioma / mortality. Meningioma / radiotherapy. Radiotherapy, Conformal / mortality. Skull Base Neoplasms / mortality. Skull Base Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Germany / epidemiology. Humans. Longitudinal Studies. Male. Middle Aged. Prognosis. Risk Assessment / methods. Risk Factors. Survival Analysis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17379447.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Maillo A, Orfao A, Espinosa AB, Sayagués JM, Merino M, Sousa P, Lara M, Tabernero MD: Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone. Neuro Oncol; 2007 Oct;9(4):438-46

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early recurrences in histologically benign/grade I meningiomas are associated with large tumors and coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone.
  • Tumor recurrence is the major clinical complication in meningiomas, and its prediction in histologically benign/grade I tumors remains a challenge.
  • In this study, we analyzed the prognostic value of specific chromosomal abnormalities and the genetic heterogeneity of the tumor, together with other clinicobiological disease features, for predicting early relapses in histologically benign/grade I meningiomas.
  • A total of 149 consecutive histologically benign/grade I meningiomas in patients who underwent complete tumor resection were prospectively analyzed.
  • Similarly, histologically benign/grade I meningiomas showing coexistence of monosomy 14 and del(1p36) in the ancestral tumor cell clone displayed a higher frequency of early relapses.
  • Our results indicate that patients with large histologically benign/grade I meningiomas carrying monosomy 14 and del(1p36) in their ancestral tumor cell clone have a high probability of relapsing early after diagnostic surgery.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Chromosome Deletion. Clone Cells. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Monosomy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1997 Jul;28(7):779-85 [9224744.001]
  • [Cites] Brain Pathol. 1990 Sep;1(1):19-24 [1688296.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Arq Neuropsiquiatr. 1997 Sep;55(3A):431-7 [9629361.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Ann Genet. 1998;41(3):164-75 [9833072.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):441-52 [9888154.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2231-9 [10327069.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80 [16467088.001]
  • [Cites] In Vivo. 2006 Mar-Apr;20(2):271-5 [16634530.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3569-77 [10589773.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):401-5 [10701525.001]
  • [Cites] Clin Neuropathol. 2000 Nov-Dec;19(6):259-67 [11128617.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):207-13 [11263500.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):377-85 [11466693.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cytometry. 2002 Jun 15;50(3):153-9 [12116338.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] BMC Cancer. 2003 Mar 4;3:6 [12614485.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3285-95 [12947064.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 15;148(2):123-8 [14734222.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Histopathology. 1993 Oct;23(4):349-53 [8300070.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] J Formos Med Assoc. 1994 Feb;93(2):145-52 [7912586.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(2-4):53-8 [8042555.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Apr;9(4):296-8 [7519053.001]
  • [Cites] Rom J Neurol Psychiatry. 1994 Oct-Dec;32(4):237-51 [7779743.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):101-4 [8548731.001]
  • [Cites] Oncogene. 1996 Apr 4;12(7):1417-23 [8622857.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):2-7; discussion 8-9 [8805134.001]
  • [Cites] J Neurosurg Sci. 1996 Mar;40(1):17-23 [8913957.001]
  • [Cites] Oncogene. 1997 Feb 6;14(5):611-6 [9053860.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):316-25 [15507670.001]
  • [Cites] J Neurosurg. 1983 Jan;58(1):51-6 [6847909.001]
  • [Cites] Acta Neuropathol. 1983;61(2):130-4 [6637397.001]
  • [Cites] J Neurosurg. 1984 Jan;60(1):52-60 [6689728.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer Genet Cytogenet. 1986 May;22(1):63-8 [3456829.001]
  • [Cites] J Neurosurg. 1986 Aug;65(2):168-71 [3723173.001]
  • [Cites] Neurochirurgie. 1986;32(2):129-34 [3724942.001]
  • [Cites] Cancer Genet Cytogenet. 1987 May;26(1):127-41 [3470128.001]
  • [Cites] Clin Neuropathol. 1989 Jan-Feb;8(1):41-4 [2706843.001]
  • [Cites] Acta Neurochir (Wien). 1989;100(3-4):104-7 [2589115.001]
  • [Cites] J Neurosurg. 1992 Oct;77(4):616-23 [1527622.001]
  • [Cites] J Med Assoc Thai. 1997 Jul;80(7):473-8 [9277078.001]
  • (PMID = 17704362.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1994101
  •  go-up   go-down


76. Mao Y, Zhou L, Zhu W, Wang X, Yang G, Xie L, Mao X, Jin K: Proliferative status of tumor stem cells may be correlated with malignancy grade of human astrocytomas. Front Biosci; 2007;12:2252-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferative status of tumor stem cells may be correlated with malignancy grade of human astrocytomas.
  • In contrast, these markers were not expressed in human capillary hemangioblastoma or meningioma.
  • The number of cells expressing Ki67 antigen and neural stem cell markers was increased in relation to worsening histological grade of astrocytomas, indicating that the capacity for tumor stem cell proliferation may be clinically relevant.
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Child, Preschool. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Middle Aged. Neurons / metabolism. Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127461.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG21980
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


77. Barresi V, Alafaci C, Salpietro F, Tuccari G: Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density? Oncol Rep; 2008 Sep;20(3):485-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density?
  • In the present study, sstr2A immunohistochemical expression was analyzed in grade II and III meningiomas and was compared with that revealed in grade I meningiomas.
  • Thirty-five formalin-fixed paraffin-embedded meningiomas, comprising 13 grade I, 19 grade II and 3 grade III tumours, according to the WHO 2007 classification, were submitted to immunohistochemical assays for sstr2A.
  • Specifically, a positive staining was found in 7/13 grade I, in 16/19 grade II and in 3/3 grade III tumours, thus demonstrating that sstr2A is frequently expressed in high grade meningiomas.
  • A significantly higher microvessel density (MVD), assessed by CD105 immunostaining and Ki-67 LI were evidenced in high grade meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Proliferation. Meningeal Neoplasms / blood supply. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neovascularization, Pathologic / pathology. Receptors, Somatostatin / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / metabolism. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Cell Surface / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695896.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / ENG protein, human; 0 / Ki-67 Antigen; 0 / Receptors, Cell Surface; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2
  •  go-up   go-down


78. Nakaya K, Chernov M, Kasuya H, Izawa M, Hayashi M, Kato K, Kubo O, Muragaki Y, Iseki H, Hori T, Okada Y, Takakura K: Risk factors for regrowth of intracranial meningiomas after gamma knife radiosurgery: importance of the histopathological grade and MIB-1 index. Minim Invasive Neurosurg; 2009 Oct;52(5-6):216-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for regrowth of intracranial meningiomas after gamma knife radiosurgery: importance of the histopathological grade and MIB-1 index.
  • INTRODUCTION: The influence of histopathological grade and MIB-1 index of intracranial meningioma on the results of its radiosurgical management is not clear.
  • Histopathological grade II or III (p<0.0001), MIB-1 index 3% and more (p=0.0004), and non-skull base location (p=0.0026) of the tumor showed negative associations with progression-free survival in multivariate analyses.
  • [MeSH-major] Antibodies, Antinuclear / metabolism. Antibodies, Monoclonal / metabolism. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Radiosurgery
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Cell Proliferation. Disease Progression. Female. Humans. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077361.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / MIB-1 antibody
  •  go-up   go-down


79. Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW: Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg; 2010 Aug;113(2):202-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas.
  • OBJECT: Despite an increased understanding of the biology of malignant meningioma tumor progression, there is a paucity of published clinical data on factors affecting outcomes following treatment for these lesions.
  • METHODS: The authors identified all patients undergoing resection of WHO Grade III tumors at their institution over a 16-year period.
  • CONCLUSIONS: Surgery is an effective treatment for WHO Grade III meningiomas at presentation and recurrence; however, aggressive attempts to achieve gross-total resection can be associated with significant neurological risk.
  • [MeSH-major] Meningeal Neoplasms. Meningioma. Neoplasm Recurrence, Local. Reoperation / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Morbidity. Proportional Hazards Models. Risk Factors. Severity of Illness Index. Treatment Outcome. World Health Organization. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 Aug;113(2):199-200; discussion 200-1 [20225919.001]
  • [CommentIn] J Neurosurg. 2015 Jun;122(6):1514-5 [25859809.001]
  • (PMID = 20225922.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


80. Rosenberg LA, Prayson RA, Lee J, Reddy C, Chao ST, Barnett GH, Vogelbaum MA, Suh JH: Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution. Int J Radiat Oncol Biol Phys; 2009 Jun 1;74(2):427-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution.
  • PURPOSE: To evaluate the outcomes for patients with Grade III meningiomas as defined by the 2007 World Health Organization standards.
  • The data from 13 patients treated between 1984 and 2006 satisfied the World Health Organization 2007 definition of Grade III meningioma.
  • CONCLUSION: This is one of the few studies reporting the outcomes for malignant meningioma patients according to recent definitions.
  • Our results are consistent with existing reports of the overall poor outcomes for atypical and malignant meningioma patients.
  • [MeSH-major] Meningeal Neoplasms / radiotherapy. Meningeal Neoplasms / surgery. Meningioma / radiotherapy. Meningioma / surgery. Salvage Therapy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / radiotherapy. Postoperative Complications. Radiosurgery. Radiotherapy / adverse effects. Radiotherapy Dosage. Survival Rate. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427553.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Otani N, Muroi C, Yano H, Khan N, Pangalu A, Yonekawa Y: Surgical management of tuberculum sellae meningioma: role of selective extradural anterior clinoidectomy. Br J Neurosurg; 2006 Jun;20(3):129-38
MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of tuberculum sellae meningioma: role of selective extradural anterior clinoidectomy.
  • Macroscopically complete removal with Simpson grade II was performed in 28 patients (87.5%).
  • [MeSH-major] Meningeal Neoplasms / surgery. Meningioma / surgery. Nerve Compression Syndromes / surgery. Sella Turcica / surgery. Skull Base Neoplasms / surgery. Vision Disorders / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Neurosurgical Procedures / methods. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16801044.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


82. Bouvier C, Liprandi A, Colin C, Giorgi R, Quilichini B, Metellus P, Figarella-Branger D: Lack of alkaline phosphatase activity predicts meningioma recurrence. Am J Clin Pathol; 2005 Aug;124(2):252-8
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of alkaline phosphatase activity predicts meningioma recurrence.
  • Reduced expression of the nonspecific tissue-type alkaline phosphatase (Pal) has been reported in high-grade meningiomas.
  • [MeSH-major] Alkaline Phosphatase / biosynthesis. Biomarkers, Tumor / analysis. Meningeal Neoplasms / enzymology. Meningioma / enzymology. Neoplasm Recurrence, Local / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Aberrations. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16040297.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


83. van Westen D, Lätt J, Englund E, Brockstedt S, Larsson EM: Tumor extension in high-grade gliomas assessed with diffusion magnetic resonance imaging: values and lesion-to-brain ratios of apparent diffusion coefficient and fractional anisotropy. Acta Radiol; 2006 Apr;47(3):311-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor extension in high-grade gliomas assessed with diffusion magnetic resonance imaging: values and lesion-to-brain ratios of apparent diffusion coefficient and fractional anisotropy.
  • MATERIAL AND METHODS: Thirty patients were studied: 18 WHO grade III or IV gliomas, 7 meningiomas, and 5 metastatic lesions.
  • [MeSH-major] Brain Edema / pathology. Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging. Glioma / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Anisotropy. Diagnosis, Differential. Diffusion. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Radiol. 2006 Apr;47(3):230 [16613301.001]
  • (PMID = 16613314.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  •  go-up   go-down


84. Fèvre-Montange M, Champier J, Durand A, Wierinckx A, Honnorat J, Guyotat J, Jouvet A: Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. Int J Oncol; 2009 Dec;35(6):1395-407
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype.
  • This microarray-based expression profiling study revealed candidate genes and pathways that may contribute to a better understanding of the recurrence of a benign meningioma.
  • [MeSH-major] Gene Expression Profiling. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Female. Gene Expression. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction


85. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, Deruty R, Moreau JJ, Fèvre-Montange M, Guyotat J: WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol; 2009 Dec;95(3):367-375
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WHO grade II and III meningiomas: a study of prognostic factors.
  • This study was performed on 199 adults treated for WHO grade II (166 patients) or grade III (33 patients) meningiomas between 1990 and 2004 in the Neurosurgery Departments of five French University Hospitals.
  • For patients with grade II meningiomas, the 5- and 10-year OS rates were 78.4 and 53.3%, respectively, while, for patients with grade III meningiomas, the corresponding values were 44.0 and 14.2%.
  • For patients with grade II meningiomas, the 5- and 10-year PFS rates were 48.4 and 22.6%, respectively, the corresponding values for patients with grade III meningiomas being 8.4 and 0%.
  • For the grade II meningiomas, univariate analysis showed that age < 60 years (P < 0.0001) and Simpson 1 resection (P = 0.055) were associated with a longer OS.
  • For the grade III meningiomas, univariate analysis showed that age < 60 years (P < 0.0001) and RT (P = 0.036) were associated with a longer OS.
  • Histological grade II was found to be associated with a longer PFS (P = 0.0032) and RT reduced the PFS in grade II meningiomas (P = 0.0006) There were no other prognostic factors in terms of PFS for grades II and III meningiomas in univariate analysis.
  • Multivariate analysis confirmed that age (< 60 years), Simpson 1 and histological grade II were independent prognostic factors for survival.
  • Prospective trials should delineate strong therapeutic guidelines for high-grade meningiomas.
  • [MeSH-major] Meningeal Neoplasms / mortality. Meningeal Neoplasms / pathology. Meningioma / mortality. Meningioma / pathology. World Health Organization
  • [MeSH-minor] Adult. Aged. Cause of Death. Databases, Factual. Disease Progression. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562258.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Barresi V, Vitarelli E, Cerasoli S, Barresi G: The cell growth inhibitory transcription factor C/EBPdelta is expressed in human meningiomas in association with low histological grade and proliferation index. J Neurooncol; 2010 Apr;97(2):233-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cell growth inhibitory transcription factor C/EBPdelta is expressed in human meningiomas in association with low histological grade and proliferation index.
  • In this study, C/EBPdelta immunohistochemical expression was assessed in 49 meningiomas of different histotype and grade and correlated with a variety of clinico-pathological data and with the overall and recurrence-free survival of the patients.
  • C/EBPdelta expression was significantly associated with a low histological grade and proliferation index, reflected by low Ki-67 labeling index (LI) and mitotic activity, and with the presence of intra-tumoral inflammatory infiltrate and the absence of necrosis.
  • [MeSH-major] CCAAT-Enhancer-Binding Protein-delta / biosynthesis. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Proliferation. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806320.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 142662-43-9 / CCAAT-Enhancer-Binding Protein-delta
  •  go-up   go-down


87. Aghi M, Barker FG 2nd: Benign adult brain tumors: an evidence-based medicine review. Prog Neurol Surg; 2006;19:80-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign adult brain tumors: an evidence-based medicine review.
  • BACKGROUND: Benign adult brain tumors can be managed conservatively or using surgery, radiation, or medicines.
  • METHODS: Review of the literature on benign adult brain tumors using evidence-based standards and focusing on meningiomas, pituitary adenomas, and vestibular schwannomas, which together represent the majority of WHO grade 1 adult brain tumors.
  • RESULTS: Nearly all studies of benign adult brain tumors were of relatively poor quality (level 3 or poorer).
  • These studies enable grade C recommendations.
  • The safety of meningioma surgery in the elderly varies with institution, radiosurgery is a reliable alternative to surgery in small to medium-sized meningiomas, and the efficacy of drugs in therapy of meningiomas recurring after surgery is difficult to interpret due to a lack of uniform criteria in the studies.
  • CONCLUSIONS: While randomized clinical trials comparing conservative management, surgery, radiation, and medical management of benign adult benign tumors are unlikely to occur, there is some level 3 evidence that can assist in their treatment.
  • [MeSH-minor] Adenoma / therapy. Adult. Humans. Meningeal Neoplasms / therapy. Meningioma / therapy. Neuroma, Acoustic / therapy. Neurosurgical Procedures. Phototherapy. Pituitary Neoplasms / therapy. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033148.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 58
  •  go-up   go-down


88. Chamberlain MC, Glantz MJ: Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer; 2008 Oct 15;113(8):2146-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas.
  • A phase 2 study was designed to estimate the 6-month progression-free survival of patients with recurrent, treatment-refractory, World Health Organization grade 1 meningiomas who were treated with interferon-alpha.
  • RESULTS: The most common grade 3 and 4 toxicities were fatigue (6 patients; 17%), anemia (3 patients; 8.6%), and leukopenia (3 patients; 8.6%) (toxicities were graded according to the National Cancer Institute's Common Toxicity Criteria [version 3.0]).
  • [MeSH-major] Interferon-alpha / therapeutic use. Meningeal Neoplasms / drug therapy. Meningioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18756531.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


89. Hsu CC, Pai CY, Kao HW, Hsueh CJ, Hsu WL, Lo CP: Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci; 2010 May;17(5):584-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do aggressive imaging features correlate with advanced histopathological grade in meningiomas?
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiography. Meningioma / pathology. Meningioma / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Imaging. Male. Middle Aged. Patient Selection. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219376.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


90. Rezanko T, Tunakan M, Kahraman A, Sucu HK, Gelal F, Akkol I: Primary rhabdoid tumor of the brain in an adult. Neuropathology; 2006 Feb;26(1):57-61
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary rhabdoid tumor of the brain in an adult.
  • The first case in the CNS was reported in 1985 and was defined as "rhabdoid tumor" initially, and was classified as grade IV in the most recent classification of the World Health Organization under the term of "atypical teratoid/rhabdoid tumor".
  • In conclusion, RT should be considered also in the differential diagnosis of intracerebral neoplasms of adult patients.
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Meningioma / pathology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • Genetic Alliance. consumer health - Brain Tumor, Adult.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16521480.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


91. Choi CY, Soltys SG, Gibbs IC, Harsh GR, Jackson PS, Lieberson RE, Chang SD, Adler JR: Cyberknife stereotactic radiosurgery for treatment of atypical (WHO grade II) cranial meningiomas. Neurosurgery; 2010 Nov;67(5):1180-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyberknife stereotactic radiosurgery for treatment of atypical (WHO grade II) cranial meningiomas.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871435.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Lai R, Crevier L, Thabane L: Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: a meta-analysis. Cancer Epidemiol Biomarkers Prev; 2005 Jul;14(7):1784-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of glutathione S-transferases and the risk of adult brain tumors: a meta-analysis.
  • BACKGROUND: Studies investigating the association between genetic polymorphisms of glutathione S-transferases (GST) and risk of adult brain tumors have reported conflicting results.
  • The rationale of this meta-analysis was to determine whether GST variants increase the susceptibility of adult brain tumors by pooling data.
  • Papers were included if they were observational studies investigating the influence of GSTM1, GSTT1, GSTP1 I105V, or GSTP1 A114V on the development of adult brain cancers.
  • RESULTS: We identified eight eligible studies, which included 1,630 cases of glioma, 245 cases of meningioma, and 7,151 controls.
  • Subgroup analyses also showed no relationship between GST variants and histopathologic groups; the overall ORs were 1.13 (95% CI, 0.88-1.43) for high-grade glioma and 1.08 (95% CI, 0.76-1.55) for low-grade glioma.
  • The T1 null genotype was significantly associated with a risk of meningioma (OR, 1.95; 95% CI, 1.02-3.76), but the M1 variant was not.
  • CONCLUSION: This study did not suggest any relationship between GST variants and risks of glioma; the T1 null genotype may influence the susceptibility of meningioma, but larger studies are needed to substantiate this relationship.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030117.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione Transferase
  • [Number-of-references] 45
  •  go-up   go-down


93. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, North American Brain Tumor Consortium: A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol; 2010 Jan;12(1):87-94
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The MTD was 650 mg/day; the observed DLTs were grade 3 rash in 2 patients at 775 mg/day.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Anticancer Drugs. 2008 Feb;19(2):209-16 [18176118.001]
  • [Cites] Eur J Clin Pharmacol. 2008 Jan;64(1):31-41 [18000659.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5349-54 [11454673.001]
  • [Cites] Neurosurgery. 2004 Jun;54(6):1480-8; discussion 1488-9 [15157306.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7727-31 [8052651.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):5079-86 [8895767.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Semin Surg Oncol. 1998 Jan-Feb;14(1):3-12 [9407626.001]
  • [Cites] Oncol Res. 1997;9(11-12):581-7 [9563005.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):162-7 [10328589.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • (PMID = 20150371.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR0865; United States / NCI NIH HHS / CA / U01 CA62399; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01-RR00079; United States / NCI NIH HHS / CA / U01CA62407-08; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / 5-U01CA62399-09; United States / NCRR NIH HHS / RR / RR003186-190379; United States / NCRR NIH HHS / RR / M01-RR00056; United States / NCI NIH HHS / CA / U01CA62421-08; United States / NCI NIH HHS / CA / CA62426; United States / NCRR NIH HHS / RR / M01 RR003186-190379; United States / NCI NIH HHS / CA / CA62422; United States / NCI NIH HHS / CA / U01CA62405; United States / NCRR NIH HHS / RR / M01 RR03186; United States / NCI NIH HHS / CA / CA62399; United States / NCI NIH HHS / CA / CA62412
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  • [Other-IDs] NLM/ PMC2940559
  •  go-up   go-down


94. Christensen HC, Schüz J, Kosteljanetz M, Poulsen HS, Boice JD Jr, McLaughlin JK, Johansen C: Cellular telephones and risk for brain tumors: a population-based, incident case-control study. Neurology; 2005 Apr 12;64(7):1189-95
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate a possible association of glioma or meningioma with use of cellular telephones, using a nationwide population-based case-control study of incident cases of meningioma and glioma.
  • METHODS: The authors ascertained all incident cases of glioma and meningioma diagnosed in Denmark between September 1, 2000, and August 31, 2002.
  • They enrolled 252 persons with glioma and 175 persons with meningioma aged 20 to 69.
  • Use of cellular telephone was associated with a low risk for high-grade glioma (OR, 0.58; 95% CI, 0.37 to 0.90).
  • The risk estimates were closer to unity for low-grade glioma (1.08; 0.58 to 2.00) and meningioma (1.00; 0.54 to 1.28).
  • CONCLUSION: The results do not support an association between use of cellular telephones and risk for glioma or meningioma.
  • [MeSH-major] Brain Neoplasms / epidemiology. Cell Phones / statistics & numerical data. Glioma / epidemiology. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology
  • [MeSH-minor] Adult. Age Distribution. Aged. Case-Control Studies. Causality. Cohort Studies. Denmark / epidemiology. Electromagnetic Fields / adverse effects. Female. Humans. Male. Middle Aged. Odds Ratio. Risk Factors. Sex Distribution. Social Class

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2006 Mar 14;66(5):781 [16534134.001]
  • [ErratumIn] Neurology. 2005 Oct 25;65(8):1324
  • (PMID = 15824345.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW: Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry; 2008 May;79(5):574-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate patient outcome and investigate the prognostic factors of high-grade meningiomas by adopting the 2000 World Health Organization (WHO) classification system.
  • METHODS: Between 1986 and 2004, 74 patients were diagnosed with high-grade meningioma: 33 with atypical and 41 with anaplastic meningioma.
  • RESULTS: Forty of 74 meningiomas were reclassified as atypical meningioma and 24 as anaplastic meningioma.
  • Overall and recurrence-free survivals were significantly longer in patients with atypical than in those with anaplastic meningioma: 142.5 versus 39.8 months and 138.5 versus 32.2 months, respectively (p<0.001).
  • In patients with anaplastic meningioma, the prognostic factors were brain invasion, adjuvant radiotherapy, malignant progression, p53 overexpression and extent of resection.
  • A precise meningioma grading system may help to avoid over-treatment of patients with an atypical meningioma as, once the tumour has "declared itself" by recurrence and histological features, it becomes a tumour that is poorly amenable to current therapies.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningioma / diagnosis
  • [MeSH-minor] Adult. Aged. Brain / pathology. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic / genetics. Humans. Ki-67 Antigen / genetics. Korea. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / classification. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome. Tumor Suppressor Protein p53 / genetics. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17766430.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


96. Gao F, You T, Lü JY, Wang YJ: [Research on the expression of cancer associated gene in the intracranial tumors]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 May;37(3):424-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Semi-quantitative RT-PCR was performed to detect the expression of CAGE gene in 17 normal tissues, 35 meningioma cases and 63 glioma cases.
  • RESULTS: The CAGE gene was expressing in none of the normal tissues except testis, but in 4 meningioma (11.3%) and 57 glioma cases(90.5%).
  • The expression of CAGE gene showed significant difference between the meningioma and glioma (P<0.001).
  • The amount of CAGE mRNA was 0.5 +/- 0.11, 0.86 +/- 0.23, 1.85 +/- 0.37 or 2.7 +/- 0.46 times of the internal control one in glioma grade I, II, or IV respectively.
  • The expression of CAGE gene increased with the pathological grade(r=0.82).
  • [MeSH-major] Brain Neoplasms / genetics. DEAD-box RNA Helicases / biosynthesis. Glioma / genetics. Meningioma / genetics
  • [MeSH-minor] Adult. Antigens, Neoplasm / biosynthesis. Antigens, Neoplasm / genetics. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761424.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; EC 3.6.1.- / DDX53 protein, human; EC 3.6.4.13 / DEAD-box RNA Helicases
  •  go-up   go-down


97. Hatiboglu MA, Cosar M, Iplikcioglu AC, Ozcan D: Sex steroid and epidermal growth factor profile of giant meningiomas associated with pregnancy. Surg Neurol; 2008 Apr;69(4):356-62; discussion 362-3
MedlinePlus Health Information. consumer health - Postpartum Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: An association between meningioma, breast cancer, and increased growth of meningiomas during pregnancy, and the luteal phase of the menstrual cycle have been shown in previous reports, but the mechanisms still remain unclear.
  • METHODS: We described 3 patients with meningioma who presented during the early postpartum period.
  • RESULTS: Pathologic studies of tumor specimens revealed atypical meningioma (grade 2), syncytial meningioma (grade 1), and transitional-psammomatous meningioma (grade 1), for cases 1, 2, and 3, respectively.
  • CONCLUSIONS: Although many reports indicating an association between meningioma and pregnancy have been published, the number of immunohistochemical studies is limited.
  • [MeSH-major] Ki-67 Antigen / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Puerperal Disorders / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptors, Steroid / metabolism
  • [MeSH-minor] Adult. Female. Humans

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707480.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Steroid; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


98. Nakane Y, Natsume A, Wakabayashi T, Oi S, Ito M, Inao S, Saito K, Yoshida J: Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurg; 2007 Aug;107(2):398-404

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to identify genes related to meningioma progression from the benign state to the atypical and anaplastic states by examining 1p LOH and the promoter methylation of RASSF1A and p73.
  • METHODS: The authors studied 40 surgical specimens (22 WHO Grade I, 11 Grade II, and seven Grade III) obtained in 37 patients with meningioma.
  • RESULTS: No 1p LOH was detected in the Grade I tumors, whereas it was detected in more than 80% of the Grade II and III tumors.
  • Methylation of the p73 promoter was observed in 81.8 and 71.4% of the Grade II and III tumors, respectively, but it was not observed in any of the Grade I tumors; methylation of the RASSF1A promoter was observed in 18.2, 63.6, and 42.9% of the Grade I, II, and III tumors, respectively.
  • Interestingly, 1p LOH and p73 promoter hypermethylation were detected in the malignantly transformed tumors but not in the lower-grade primary ones.
  • CONCLUSIONS: Based on the hypothesis that meningiomas cumulatively acquire genetic alterations and thus progress from the benign to the atypical and anaplastic states, genetic alterations in the methylation status of p73 or RASSF1A along with 1p LOH may result in the malignant transformation of a meningioma.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. DNA-Binding Proteins / genetics. Loss of Heterozygosity / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Nuclear Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic / genetics. DNA Methylation. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695396.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


99. Schittenhelm J, Mittelbronn M, Roser F, Tatagiba M, Mawrin C, Bornemann A: Patterns of SPARC expression and basement membrane intactness at the tumour-brain border of invasive meningiomas. Neuropathol Appl Neurobiol; 2006 Oct;32(5):525-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study we aimed at determining the relationship of basement membrane intactness and SPARC protein expression at the meningioma-brain border.
  • Sections of 51 brain-invasive meningiomas (31 meningothelial meningiomas WHO grade I, 11 atypical WHO grade II, and nine anaplastic WHO grade III tumours) were immunolabelled with antibodies against SPARC, epithelial membrane antigen (EMA), collagen IV and glial fibrillary acidic protein (GFAP).
  • Twenty-two non-invasive WHO grade I meningothelial meningiomas were included in the study for comparison.
  • By contrast, the number of WHO grade I tumours expressing collagen IV (15/31) was highly significantly elevated when compared with WHO grade II (1/11) and WHO grade III (0/9) (both P < 0.0001).
  • In conclusion, the destruction of the basement membrane is correlated with meningioma malignancy grade whereas the expression of SPARC protein at the tumour-brain border is not.
  • [MeSH-major] Basement Membrane / pathology. Brain / pathology. Brain Neoplasms / pathology. Meningioma / pathology. Osteonectin / biosynthesis. Osteonectin / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Chemistry / genetics. Collagen Type IV / metabolism. Cytoplasm / metabolism. Cytoplasm / pathology. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972886.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Collagen Type IV; 0 / Glial Fibrillary Acidic Protein; 0 / Osteonectin
  •  go-up   go-down


100. Boldrini L, Pistolesi S, Gisfredi S, Ursino S, Alì G, Pieracci N, Basolo F, Parenti G, Fontanini G: Expression of endothelin 1 and its angiogenic role in meningiomas. Virchows Arch; 2006 Nov;449(5):546-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ET-1 may be involved in meningioma tumourigenesis in concert with other growth factors, in particular with angiogenic agents.
  • We analysed ET-1 expression by immunohistochemistry and its activating system by reverse-transcription-polymerase chain reaction in 56 cases of meningioma.
  • We found an association between high-grade meningiomas and high ET-1 expression levels (p=0.002).
  • ET-1 may contribute to meningioma growth by inducing formation of new blood vessels.
  • The association of ET-1 and meningioma represents a potential area for therapeutic intervention with selective ET inhibitors.
  • [MeSH-major] Endothelin-1 / physiology. Meningeal Neoplasms / blood supply. Meningioma / blood supply. Neovascularization, Physiologic
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. RNA, Messenger / analysis. Vascular Endothelial Growth Factor A / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17013629.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Endothelin-1; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down






Advertisement